🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 73 (from laksa119)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa073.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'https://www.hcplive.com/view/is-alternative-medicine-to-blame-for-the-death-of-steve-jobs\')), getAhrefsUnparsedNoserviceFromURL(\'https://www.hcplive.com/view/is-alternative-medicine-to-blame-for-the-death-of-steve-jobs\'))) FORMAT JSONEachRow'

Response:

{"found_url":"https:\/\/www.hcplive.com\/view\/is-alternative-medicine-to-blame-for-the-death-of-steve-jobs","crawl_time":1776252049,"first_indexed_time":1669870942,"http_code":200,"src_unparsed":"com,hcplive!www,\/view\/is-alternative-medicine-to-blame-for-the-death-of-steve-jobs s443","src_root_hash":"1719923596006174473","history_drop_reason":null,"meta_title":"Is Alternative Medicine to Blame for the Death of Steve Jobs? | HCPLive","meta_descriptions":["Although alternative medicine is a good compliment to conventional medical treatment, Steve Jobs' sole reliance on alternative medicine treatment may be the primary factor for his untimely death."],"attrs_boilerpipe_text":"Although alternative medicine is a good compliment to conventional medical treatment, Steve Jobs' sole reliance on alternative medicine treatment may be the primary factor for his untimely death.\nWhen doctors first discovered the tumor in his pancreas in 2003, Steve Jobs was told that, with immediate surgery, the tumor could be removed and he had a high possibility of being cured.  Instead, the co-founder of Apple declined the surgery and focused on using alternative medicine to treat his disease.  Harvard medical school researcher, Dr. Ramzi Amri, referred to Jobs’ death at age 56, “unnecessarily early” due to his reliance on alternative medicine.\nAmri argued that Jobs reduced his chances of survival by resisting his doctors’ recommendations of immediate surgery after the 2003 diagnosis.  “Given the circumstances it seems sound to assume that Mr. Jobs’ choice for alternative medicine could have led to an unnecessarily early death.” He added that based on his own research and other sources from biomedical research, the neuroendocrine tumor that Jobs was diagnosed with could have been cured had it not been for his decision to try alternative medicine.\nSteve Jobs' Trust in Alternative Medicine Likely Shortened His Life, Researcher Contends\n[New York Daily News]\nAfter nine months of undergoing alternative medicine treatments for his disease, Jobs decided to allow for the use of conventional medicine in July 2004 due to the size of his tumor increasing.  Jobs practiced Buddhism and was reportedly skeptical about mainstream medicine, instead stubbornly believing in unconventional methods to cure his ailments.  Still, Dr. Jeffrey A. Norton, chief of surgical oncology at Stanford University, stated, “surgery is the only treatment modality that can result in a cure.”  Norton was the one who removed Jobs’ tumor but alternative forms of treatment, such as a specialized diet and different meditation exercises, could have ultimately cost Jobs his life.\nBuddhist theories of medicine point to “three poisons” that cause people to get sick: greed, anger, and ignorance.  Yet, why would a man who is so technologically-savvy as Steve Jobs be basing such important health decisions on ancient philosophies and natural remedies, especially when there have recently been more breakthroughs in cancer research than at any other point in history?\nDid \"Alternative Medicine\" Kill Steve Jobs?\n[CelebrityDiagnosis.com]\nIn terms of his alternative medicine treatments, it is still not known what exactly Jobs did to treat his cancer.  He did reportedly restrict his diet to only fruits or fruits and vegetables, consulted psychics, and tried a procedure known as hydrotherapy.  Surgical removal of the tumor for patients whose disease is detected while it is still confined to the pancreas, have a five-year survival rate of 87 percent.  Thus, the majority of patients live for quite a while.\nIt is impossible to know whether surgery would have cured Jobs of his disease but his alternative medicine techniques, like acupuncture, were “not enough to change the course of the disease,” says Dr. Lowell Kobrin, a medical doctor who now focuses on acupuncture and herbal medicine at Northbend Medical Center in Coos Bay, Oregon. Kobrin added that the therapy could not affect cancer itself.  Tim Birdsall, vice president of integrative medicine at the Cancer Treatment Centers of America, stated, “Once a cancer is established, in the vast majority of cases, simply changing the environment will not be sufficient to eradicate that established tumor.”  While alternative medicine seems to be a beneficial compliment to conventional medicine, it cannot replace conventional medicine when trying to cure a dangerous disease.\nDid Alternative Medicine Extend or Abbreviate Steve Jobs' Life?\n[Scientific American]\nDue to Jobs’ form of pancreatic cancer being less lethal that the most common form of pancreatic cancer known as adenocarcinoma, many experts believe that his decision to wait before opting for surgery was not necessarily a bad idea.  Julie Fleshman, president and chief executive officer of the Pancreatic Cancer Action Network, said that patients in Jobs’ situation don’t automatically have to rush treatment.  “The length of time before you have to make a decision about your treatment is not as quick as someone whose been diagnosed with an adenocarcinoma,” she added.\nDr. Maged Rizk, a gastroenterologist at Cleveland Clinic, believed that Jobs waiting nine months for surgery was a bad decision.  She said, “if it is an islet-cell tumor and the cells are [typical of early cancer], and as long as you don’t have symptoms, you can sit on it a bit.” Still, both Fleshman and Rizk agreed that alternative medicine treatments should not have been the sole methods of treatment for his disease.\nDid Alternative Medicine Kill Steve Jobs?\n[LiveScience.com]\nWith the general consensus of medical experts being against the singular use of alternative medicine without conventional treatment, Steve Jobs agreed with them toward the end.  Walter Isaacson, whose much-anticipated authorized biography on Jobs’ life is was released earlier this month, said that, before he died, the 56-year old Jobs had come to realize the mistake he made regarding his treatment.  Isaacson said Jobs “wanted to talk about it, how he regretted it.  I think he felt he should have been operated on [it] sooner.”\nJobs was pushed to embrace conventional medicine by many confidants, including his sister, Mona Simpson, and Art Levinson, an Apple board member.  In the end, Jobs realized the mistake he made and regretted the decision he made to fight the disease that plagued him for so many years.\nSteve Jobs 'Regretted Trying to Beat Cancer with Alternative Medicine for So Long'\n[The Telegraph]\nNewsletter\nJoin thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.","attrs_markdown":"[![](https:\/\/www.hcplive.com\/logo.webp)](https:\/\/www.hcplive.com\/)\n\n[News](https:\/\/www.hcplive.com\/news)\n\nMedia\n\n[Clinical Forum Insights](https:\/\/www.hcplive.com\/clinical-forum-insights)[Podcasts](https:\/\/www.hcplive.com\/podcasts)[Shorts](https:\/\/www.hcplive.com\/shorts)[State Of Sciences - Presentations](https:\/\/www.hcplive.com\/state-of-sciences-presentations)[Videos](https:\/\/www.hcplive.com\/videos)[Webinars](https:\/\/www.hcplive.com\/webinars)\n\nMultimedia Series\n\n[CURE Connections®](https:\/\/www.hcplive.com\/cure-connections)[Insights](https:\/\/www.hcplive.com\/insights)[Medcast](https:\/\/www.hcplive.com\/medcast)[Peer Exchange](https:\/\/www.hcplive.com\/peer-exchange)[Peers & Perspectives](https:\/\/www.hcplive.com\/peers-and-perspective)[Special Report](https:\/\/www.hcplive.com\/special-report)\n\nConferences\n\n[Conference Coverage](https:\/\/www.hcplive.com\/latest-conference)[Conference Listing](https:\/\/www.hcplive.com\/conference)\n\nMore\n\n[Partners](https:\/\/www.hcplive.com\/sap-partner)\n\n[CME\/CE](https:\/\/www.hcplive.com\/continuing-education)\n\nResources\n\n[Digital Supplements](https:\/\/www.hcplive.com\/journals\/supplements\/digital-supplement)[Interactive Tools](https:\/\/www.hcplive.com\/interactive-tools)[Live Events](https:\/\/www.hcplive.com\/events)[Press Release](https:\/\/www.hcplive.com\/press-release)[Publications](https:\/\/www.hcplive.com\/journals)[Sponsored](https:\/\/www.hcplive.com\/sponsored)\n\n[Advisory Board](https:\/\/www.hcplive.com\/advisory-board)\n\n[Subscribe](https:\/\/www.hcplive.com\/subscribe)\n\nMy Account\n\n- [News](https:\/\/www.hcplive.com\/news)\n- Media\n- Multimedia Series\n- Conferences\n- [Partners](https:\/\/www.hcplive.com\/sap-partner)\n- [CME\/CE](https:\/\/www.hcplive.com\/continuing-education)\n- Resources\n- [Advisory Board](https:\/\/www.hcplive.com\/advisory-board)\n- [Subscribe](https:\/\/www.hcplive.com\/subscribe)\n\n- [Allergy](https:\/\/www.hcplive.com\/clinical\/allergy)\n  - [Seasonal Allergy](https:\/\/www.hcplive.com\/clinical\/seasonal-allergy)\n  - [Food Allergy](https:\/\/www.hcplive.com\/clinical\/food-allergy)\n  - [Anaphylaxis](https:\/\/www.hcplive.com\/clinical\/anaphylaxis)\n- [Biosimilars](https:\/\/www.hcplive.com\/clinical\/biosimilars)\n- [Cardiology](https:\/\/www.hcplive.com\/clinical\/cardiology)\n  - [Dyslipidemia](https:\/\/www.hcplive.com\/clinical\/dyslipidemia)\n  - [Arrhythmia](https:\/\/www.hcplive.com\/clinical\/arrhythmia)\n  - [Cardiomyopathy](https:\/\/www.hcplive.com\/clinical\/cardiomyopathy)\n  - [Structural Heart Disease](https:\/\/www.hcplive.com\/clinical\/structural-heart-disease)\n  - [Atherosclerotic Cardiovascular Disease](https:\/\/www.hcplive.com\/clinical\/atherosclerotic-cardiovascular-disease)\n  - [Heart Failure](https:\/\/www.hcplive.com\/clinical\/heart-failure)\n  - [Hypertension](https:\/\/www.hcplive.com\/clinical\/hypertension)\n  - [Stroke](https:\/\/www.hcplive.com\/clinical\/stroke)\n  - [Venous Thromboembolism](https:\/\/www.hcplive.com\/clinical\/vte)\n- [Dermatology](https:\/\/www.hcplive.com\/clinical\/dermatology)\n  - [Alopecia](https:\/\/www.hcplive.com\/clinical\/alopecia)\n  - [Vitiligo](https:\/\/www.hcplive.com\/clinical\/vitiligo)\n  - [Hidradenitis Suppurativa](https:\/\/www.hcplive.com\/clinical\/hidradenitis-suppurativa)\n  - [Acne](https:\/\/www.hcplive.com\/clinical\/acne)\n  - [Atopic Dermatitis](https:\/\/www.hcplive.com\/clinical\/atopic-dermatitis)\n  - [Urticaria](https:\/\/www.hcplive.com\/clinical\/chronic-idiopathic-urticaria)\n  - [Plaque Psoriasis](https:\/\/www.hcplive.com\/clinical\/plaque-psoriasis)\n  - [Rosacea](https:\/\/www.hcplive.com\/clinical\/rosacea)\n- [Endocrinology](https:\/\/www.hcplive.com\/clinical\/endocrinology)\n  - [Type 2 Diabetes](https:\/\/www.hcplive.com\/clinical\/type-2-diabetes)\n  - [Type 1 Diabetes](https:\/\/www.hcplive.com\/clinical\/type-1-diabetes)\n  - [Polycystic Ovary Syndrome](https:\/\/www.hcplive.com\/clinical\/polycystic-ovary-syndrome)\n  - [Hormonal Disorders](https:\/\/www.hcplive.com\/clinical\/hormonal-disorders)\n  - [Thyroid Disorders](https:\/\/www.hcplive.com\/clinical\/thyroid-disorders)\n- [FDA News](https:\/\/www.hcplive.com\/clinical\/fda-news)\n- [Family Medicine](https:\/\/www.hcplive.com\/clinical\/family-medicine)\n  - [Influenza](https:\/\/www.hcplive.com\/clinical\/influenza)\n  - [Vaccination](https:\/\/www.hcplive.com\/clinical\/vaccination)\n- [Gastroenterology](https:\/\/www.hcplive.com\/clinical\/gastroenterology)\n  - [Exocrine Pancreatic Insufficiency](https:\/\/www.hcplive.com\/clinical\/exocrine-pancreatic-insufficiency)\n  - [Inflammatory Bowel Disease](https:\/\/www.hcplive.com\/clinical\/ibd)\n  - [C Difficile Infection](https:\/\/www.hcplive.com\/clinical\/c-difficile-resources)\n  - [Gastroesophageal Reflux Disease (GERD)](https:\/\/www.hcplive.com\/clinical\/gastroesophageal-reflux-disease)\n  - [Irritable Bowel Syndrome](https:\/\/www.hcplive.com\/clinical\/irritable-bowel-syndrome)\n  - [Peptic Ulcer](https:\/\/www.hcplive.com\/clinical\/peptic-ulcer)\n  - [Ulcerative Colitis](https:\/\/www.hcplive.com\/clinical\/ulcerative-colitis)\n- [Geriatrics](https:\/\/www.hcplive.com\/clinical\/geriatrics)\n  - [Dementia and Alzheimer Disease](https:\/\/www.hcplive.com\/clinical\/alzheimer-disease)\n  - [Parkinson Disease](https:\/\/www.hcplive.com\/clinical\/parkinsons-disease)\n- [Hematology](https:\/\/www.hcplive.com\/clinical\/hematology)\n  - [Paroxysmal Nocturnal Hemoglobinuria](https:\/\/www.hcplive.com\/clinical\/paroxysmal-nocturnal-hemoglobinuria)\n  - [Anemia](https:\/\/www.hcplive.com\/clinical\/anemia)\n  - [Sickle Cell](https:\/\/www.hcplive.com\/clinical\/sickle-cell)\n- [Hepatology](https:\/\/www.hcplive.com\/clinical\/hepatology)\n  - [Alpha-1 antitrypsin deficiency](https:\/\/www.hcplive.com\/clinical\/aatd)\n  - [Cholangitis](https:\/\/www.hcplive.com\/clinical\/cholangitis)\n  - [MASH \/ MASLD](https:\/\/www.hcplive.com\/clinical\/mash-masld)\n  - [Hepatitis C](https:\/\/www.hcplive.com\/clinical\/hepatitis-c)\n- [Hospital Medicine](https:\/\/www.hcplive.com\/clinical\/hospital-medicine)\n- [Infectious Disease](https:\/\/www.hcplive.com\/clinical\/infectious-disease)\n  - [COVID-19](https:\/\/www.hcplive.com\/clinical\/coronavirus)\n  - [HIV\/AIDS](https:\/\/www.hcplive.com\/clinical\/hiv-aids)\n- [Internal Medicine](https:\/\/www.hcplive.com\/clinical\/internal-medicine)\n- [Nephrology](https:\/\/www.hcplive.com\/clinical\/nephrology)\n  - [C3 Glomerulopathy](https:\/\/www.hcplive.com\/clinical\/c3-glomerulopathy)\n  - [IgA Nephropathy](https:\/\/www.hcplive.com\/clinical\/berger-disease)\n  - [Focal Segmental Glomerulosclerosis](https:\/\/www.hcplive.com\/clinical\/focal-segmental-glomerulosclerosis)\n  - [Chronic Kidney Disease](https:\/\/www.hcplive.com\/clinical\/chronic-kidney-disease)\n- [Neurology](https:\/\/www.hcplive.com\/clinical\/neurology)\n  - [Epilepsy](https:\/\/www.hcplive.com\/clinical\/epilepsy)\n  - [Migraine](https:\/\/www.hcplive.com\/clinical\/migraine)\n  - [Tardive Dyskinesia](https:\/\/www.hcplive.com\/clinical\/tardive-dyskinesia)\n  - [Traumatic Brain Injury](https:\/\/www.hcplive.com\/clinical\/tbi)\n- [Obesity Management](https:\/\/www.hcplive.com\/clinical\/obesity-management)\n- [Ophthalmology](https:\/\/www.hcplive.com\/clinical\/ophthalmology)\n  - [Geographic Atrophy](https:\/\/www.hcplive.com\/clinical\/geographic-atrophy)\n  - [Age-Related Macular Degeneration](https:\/\/www.hcplive.com\/clinical\/amd)\n  - [Diabetic Macular Edema](https:\/\/www.hcplive.com\/clinical\/diabetic-macular-edema)\n  - [Uveitis](https:\/\/www.hcplive.com\/clinical\/uveitis)\n- [Pain](https:\/\/www.hcplive.com\/clinical\/pain)\n  - [Acute Pain](https:\/\/www.hcplive.com\/clinical\/acute-pain)\n  - [Chronic Pain](https:\/\/www.hcplive.com\/clinical\/chronic-pain)\n  - [Multiple Sclerosis](https:\/\/www.hcplive.com\/clinical\/multiple-sclerosis)\n  - [Neuropathic Pain](https:\/\/www.hcplive.com\/clinical\/neuropathic-pain)\n- [Pediatrics](https:\/\/www.hcplive.com\/clinical\/pediatrics)\n- [Psychiatry](https:\/\/www.hcplive.com\/clinical\/psychiatry)\n  - [PTSD](https:\/\/www.hcplive.com\/clinical\/ptsd)\n  - [Addiction](https:\/\/www.hcplive.com\/clinical\/addiction)\n  - [ADHD](https:\/\/www.hcplive.com\/clinical\/adhd)\n  - [Bipolar Disorder](https:\/\/www.hcplive.com\/clinical\/bipolar-disorder)\n  - [Major Depressive Disorder](https:\/\/www.hcplive.com\/clinical\/major-depressive-disorder)\n  - [Schizophrenia](https:\/\/www.hcplive.com\/clinical\/schizophrenia)\n- [Pulmonology](https:\/\/www.hcplive.com\/clinical\/pulmonology)\n  - [Lung Cancer](https:\/\/www.hcplive.com\/clinical\/lung-cancer)\n  - [Pulmonary Fibrosis](https:\/\/www.hcplive.com\/clinical\/pulmonary-fibrosis)\n  - [Asthma](https:\/\/www.hcplive.com\/clinical\/asthma)\n  - [COPD](https:\/\/www.hcplive.com\/clinical\/copd)\n- [RDR Alert®](https:\/\/www.hcplive.com\/clinical\/rare-diseases)\n  - [Vasculitis](https:\/\/www.hcplive.com\/clinical\/vasculitis)\n  - [Amyloidosis](https:\/\/www.hcplive.com\/clinical\/amyloidosis)\n  - [Huntington Disease](https:\/\/www.hcplive.com\/clinical\/huntington-disease)\n  - [Lysosomal Storage Disorders](https:\/\/www.hcplive.com\/clinical\/lysosomal-storage-disorders)\n- [Rheumatology](https:\/\/www.hcplive.com\/clinical\/rheumatology)\n- [Sleep](https:\/\/www.hcplive.com\/clinical\/sleep)\n  - [Obstructive Sleep Apnea](https:\/\/www.hcplive.com\/clinical\/obstructive-sleep-apnea)\n  - [Insomnia](https:\/\/www.hcplive.com\/clinical\/insomnia)\n- [Surgery](https:\/\/www.hcplive.com\/clinical\/surgery)\n  - [Plastic surgery](https:\/\/www.hcplive.com\/clinical\/plastic-surgery)\n- [Women's Health](https:\/\/www.hcplive.com\/clinical\/womens-health)\n\nChoose Specialty\n\nSpotlight -\n\n[FDA News](https:\/\/www.hcplive.com\/clinical\/fda-news)\\|\n\n[This Year In Medicine 2025](https:\/\/www.hcplive.com\/this-year-in-medicine)\n\nAdvertisement\n\n\\|Articles\\|October 31, 2011\n\n# Is Alternative Medicine to Blame for the Death of Steve Jobs?\nAuthor(s)[*Will Bonesso*](https:\/\/www.hcplive.com\/authors\/will-bonesso)\n\nAlthough alternative medicine is a good compliment to conventional medical treatment, Steve Jobs' sole reliance on alternative medicine treatment may be the primary factor for his untimely death.\n\nAdvertisement\n\n![](https:\/\/cdn.sanity.io\/images\/0vv8moc6\/hcplive\/5f9cfbc7d54755c137d9c53fe0ce60044356bfb4-300x150.jpg?w=300&max-h=150&fit=crop&auto=format)\n\n![](https:\/\/cdn.sanity.io\/images\/0vv8moc6\/hcplive\/5f9cfbc7d54755c137d9c53fe0ce60044356bfb4-300x150.jpg?fit=crop&auto=format)\n\nWhen doctors first discovered the tumor in his pancreas in 2003, Steve Jobs was told that, with immediate surgery, the tumor could be removed and he had a high possibility of being cured. Instead, the co-founder of Apple declined the surgery and focused on using alternative medicine to treat his disease. Harvard medical school researcher, Dr. Ramzi Amri, referred to Jobs’ death at age 56, “unnecessarily early” due to his reliance on alternative medicine.\n\nAmri argued that Jobs reduced his chances of survival by resisting his doctors’ recommendations of immediate surgery after the 2003 diagnosis. “Given the circumstances it seems sound to assume that Mr. Jobs’ choice for alternative medicine could have led to an unnecessarily early death.” He added that based on his own research and other sources from biomedical research, the neuroendocrine tumor that Jobs was diagnosed with could have been cured had it not been for his decision to try alternative medicine.\n\n[Steve Jobs' Trust in Alternative Medicine Likely Shortened His Life, Researcher Contends](http:\/\/articles.nydailynews.com\/2011-10-14\/news\/30293918_1_alternative-medicine-pancreatic-cancer-neuroendocrine-tumor) **\\[New York Daily News\\]**\n\nAfter nine months of undergoing alternative medicine treatments for his disease, Jobs decided to allow for the use of conventional medicine in July 2004 due to the size of his tumor increasing. Jobs practiced Buddhism and was reportedly skeptical about mainstream medicine, instead stubbornly believing in unconventional methods to cure his ailments. Still, Dr. Jeffrey A. Norton, chief of surgical oncology at Stanford University, stated, “surgery is the only treatment modality that can result in a cure.” Norton was the one who removed Jobs’ tumor but alternative forms of treatment, such as a specialized diet and different meditation exercises, could have ultimately cost Jobs his life.\n\nBuddhist theories of medicine point to “three poisons” that cause people to get sick: greed, anger, and ignorance. Yet, why would a man who is so technologically-savvy as Steve Jobs be basing such important health decisions on ancient philosophies and natural remedies, especially when there have recently been more breakthroughs in cancer research than at any other point in history?\n\n[Did \"Alternative Medicine\" Kill Steve Jobs?](http:\/\/www.celebritydiagnosis.com\/2011\/10\/did-alternative-medicine-kill-steve-jobs\/) **\\[CelebrityDiagnosis.com\\]**\n\nIn terms of his alternative medicine treatments, it is still not known what exactly Jobs did to treat his cancer. He did reportedly restrict his diet to only fruits or fruits and vegetables, consulted psychics, and tried a procedure known as hydrotherapy. Surgical removal of the tumor for patients whose disease is detected while it is still confined to the pancreas, have a five-year survival rate of 87 percent. Thus, the majority of patients live for quite a while.\n\nIt is impossible to know whether surgery would have cured Jobs of his disease but his alternative medicine techniques, like acupuncture, were “not enough to change the course of the disease,” says Dr. Lowell Kobrin, a medical doctor who now focuses on acupuncture and herbal medicine at Northbend Medical Center in Coos Bay, Oregon. Kobrin added that the therapy could not affect cancer itself. Tim Birdsall, vice president of integrative medicine at the Cancer Treatment Centers of America, stated, “Once a cancer is established, in the vast majority of cases, simply changing the environment will not be sufficient to eradicate that established tumor.” While alternative medicine seems to be a beneficial compliment to conventional medicine, it cannot replace conventional medicine when trying to cure a dangerous disease.\n\n[Did Alternative Medicine Extend or Abbreviate Steve Jobs' Life?](http:\/\/www.scientificamerican.com\/article.cfm?id=alternative-medicine-extend-abbreviate-steve-jobs-life&page=3) **\\[Scientific American\\]**\n\nDue to Jobs’ form of pancreatic cancer being less lethal that the most common form of pancreatic cancer known as adenocarcinoma, many experts believe that his decision to wait before opting for surgery was not necessarily a bad idea. Julie Fleshman, president and chief executive officer of the Pancreatic Cancer Action Network, said that patients in Jobs’ situation don’t automatically have to rush treatment. “The length of time before you have to make a decision about your treatment is not as quick as someone whose been diagnosed with an adenocarcinoma,” she added.\n\nDr. Maged Rizk, a gastroenterologist at Cleveland Clinic, believed that Jobs waiting nine months for surgery was a bad decision. She said, “if it is an islet-cell tumor and the cells are \\[typical of early cancer\\], and as long as you don’t have symptoms, you can sit on it a bit.” Still, both Fleshman and Rizk agreed that alternative medicine treatments should not have been the sole methods of treatment for his disease.\n\n[Did Alternative Medicine Kill Steve Jobs?](http:\/\/www.livescience.com\/16551-steve-jobs-alternative-medicine-pancreatic-cancer-treatment.html) **\\[LiveScience.com\\]**\n\nWith the general consensus of medical experts being against the singular use of alternative medicine without conventional treatment, Steve Jobs agreed with them toward the end. Walter Isaacson, whose much-anticipated authorized biography on Jobs’ life is was released earlier this month, said that, before he died, the 56-year old Jobs had come to realize the mistake he made regarding his treatment. Isaacson said Jobs “wanted to talk about it, how he regretted it. I think he felt he should have been operated on \\[it\\] sooner.”\n\nJobs was pushed to embrace conventional medicine by many confidants, including his sister, Mona Simpson, and Art Levinson, an Apple board member. In the end, Jobs realized the mistake he made and regretted the decision he made to fight the disease that plagued him for so many years.\n\n[Steve Jobs 'Regretted Trying to Beat Cancer with Alternative Medicine for So Long'](http:\/\/www.telegraph.co.uk\/technology\/apple\/8841347\/Steve-Jobs-regretted-trying-to-beat-cancer-with-alternative-medicine-for-so-long.html) **\\[The Telegraph\\]**\n\n### Newsletter\nJoin thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.\n\n[Subscribe Now\\!](https:\/\/www.hcplive.com\/subscribe)\n\nAdvertisement\n***\n## Related Content\nAdvertisement\n\n[![Clinicians Encounter Patient Use of AI for Mental Health, With Darlene King, MD](https:\/\/cdn.sanity.io\/images\/0vv8moc6\/hcplive\/df61ec121213f81480f734b84f7d74d23faaee8e-1200x628.png?w=350&fit=crop&auto=format)](https:\/\/www.hcplive.com\/view\/clinicians-encounter-patient-use-ai-mental-health-darlene-king-md)\n\n[Clinicians Encounter Patient Use of AI for Mental Health, With Darlene King, MD](https:\/\/www.hcplive.com\/view\/clinicians-encounter-patient-use-ai-mental-health-darlene-king-md)\n\nBy[Darlene King, MD](https:\/\/www.hcplive.com\/authors\/darlene-king-md)\n\nApril 14th 2026\n\n[![Alexander Blood, MD \\| Image Credit: American Heart Association](https:\/\/cdn.sanity.io\/images\/0vv8moc6\/hcplive\/54fb6a62d78a54faf41e4db054129a4d4474da69-1200x628.png?w=350&fit=crop&auto=format)](https:\/\/www.hcplive.com\/view\/ai-model-outperforms-clinicians-in-hcm-registry-data-extraction-with-alexander-blood-md)\n\n[AI Model Outperforms Clinicians in HCM Registry Data Extraction, With Alexander Blood, MD](https:\/\/www.hcplive.com\/view\/ai-model-outperforms-clinicians-in-hcm-registry-data-extraction-with-alexander-blood-md)\n\nBy[Alexander Blood, MD](https:\/\/www.hcplive.com\/authors\/alexander-blood-md)\n\nApril 14th 2026\n\n[![Rebuilding Trust, Increasing Living Donor Transplant In Black Kidney Candidates, With Pranav Garimella, MBBS, MPH](https:\/\/cdn.sanity.io\/images\/0vv8moc6\/hcplive\/17079c2da7bfddb0f6cb2f5b8ebaf40ba27017a4-1200x628.png?w=350&fit=crop&auto=format)](https:\/\/www.hcplive.com\/view\/rebuilding-trust-increasing-living-donor-transplant-black-kidney-candidates-pranav-garimella)\n\n[Rebuilding Trust, Increasing Living Donor Transplant In Black Kidney Candidates, With Pranav Garimella, MBBS, MPH](https:\/\/www.hcplive.com\/view\/rebuilding-trust-increasing-living-donor-transplant-black-kidney-candidates-pranav-garimella)\n\nBy[Pranav Garimella, MBBS, MPH](https:\/\/www.hcplive.com\/authors\/pranav-garimella-mbbs-mph)\n\nApril 14th 2026\n\n[![Brensocatib Phase 2b Study in HS Does Not Meet Endpoints, Program Discontinued](https:\/\/cdn.sanity.io\/images\/0vv8moc6\/hcplive\/d8048845deac2eba53b8f3a6afcc75a830fb4036-1200x630.png?w=350&fit=crop&auto=format)](https:\/\/www.hcplive.com\/view\/brensocatib-phase-2b-study-hs-does-not-meet-endpoints-program-discontinued)\n\n[Brensocatib Phase 2b Study in HS Does Not Meet Endpoints, Program Discontinued](https:\/\/www.hcplive.com\/view\/brensocatib-phase-2b-study-hs-does-not-meet-endpoints-program-discontinued)\n\nBy[Tim Smith](https:\/\/www.hcplive.com\/authors\/tim-smith)\n\nApril 14th 2026\n\n[![Short Sleep Tied to Next-Day Depression in Suicidal Youth, With Delainey Wescott, PhD](https:\/\/cdn.sanity.io\/images\/0vv8moc6\/hcplive\/0c6a5d3b4e4635a39ca44d92ef7d00dd54cbcb4c-1200x628.png?w=350&fit=crop&auto=format)](https:\/\/www.hcplive.com\/view\/short-sleep-tied-next-day-depression-suicidal-youth-delainey-wescott-phd)\n\n[Short Sleep Tied to Next-Day Depression in Suicidal Youth, With Delainey Wescott, PhD](https:\/\/www.hcplive.com\/view\/short-sleep-tied-next-day-depression-suicidal-youth-delainey-wescott-phd)\n\nBy[Delainey Wescott, PhD](https:\/\/www.hcplive.com\/authors\/delainey-wescott-phd)\n\nApril 14th 2026\n\n## Latest CME\n[![20th Annual Controversies in Modern Eye Care](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/l01hgc5xkksh-CIME26TICatalog750x361.png) In-Person Event20th Annual Controversies in Modern Eye Care April 19, 2026](https:\/\/www.gotoper.com\/courses\/cime?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[Register now\\!](https:\/\/www.gotoper.com\/courses\/cime?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/4p61lbi98jvq-TICatalog750x3612x631.png) Video(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments Yasha Modi, MD; Carolyn Majcher, OD, FAAO, FORS](https:\/\/www.gotoper.com\/courses\/clinical-consultations-framing-a-new-approach-to-geographic-atrophy-management-expert-insights-into-recent-developments?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/clinical-consultations-framing-a-new-approach-to-geographic-atrophy-management-expert-insights-into-recent-developments?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/4p61lbi98jvq-TICatalog750x3612x631.png) Video(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments Yasha Modi, MD; Carolyn Majcher, OD, FAAO, FORS](https:\/\/www.gotoper.com\/courses\/clinical-consultations-framing-a-new-approach-to-geographic-atrophy-management-expert-insights-into-recent-developments?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/clinical-consultations-framing-a-new-approach-to-geographic-atrophy-management-expert-insights-into-recent-developments?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Addressing Unmet Needs in HER2+ Metastatic BTC](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/rz7ssigwynji-PER_PodSeries_BTC_Pod1_TICatalog750x3612x.png) VideoAddressing Unmet Needs in HER2+ Metastatic BTC Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA](https:\/\/www.gotoper.com\/courses\/addressing-unmet-needs-in-her2-metastatic-btc?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/addressing-unmet-needs-in-her2-metastatic-btc?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/lan4sozx8lsu-Roswell25TICatalog750x361.png) In-Person + Virtual EventUpstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting April 25-26, 2026](https:\/\/www.gotoper.com\/courses\/upstate-new-york-hematology-hematologic-oncology-conference-a-review-of-the-67th-ash-annual-meeting?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/upstate-new-york-hematology-hematologic-oncology-conference-a-review-of-the-67th-ash-annual-meeting?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/1r1apfwoh975-ADCCDKArchiveBanners_TIDetail800x450.jpg) VideoCase-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD](https:\/\/www.gotoper.com\/courses\/case-by-case-application-of-hif-phis-for-the-treatment-of-anemia-in-patients-with-ckd-f7al?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/case-by-case-application-of-hif-phis-for-the-treatment-of-anemia-in-patients-with-ckd-f7al?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/1r1apfwoh975-ADCCDKArchiveBanners_TIDetail800x450.jpg) VideoCase-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD](https:\/\/www.gotoper.com\/courses\/case-by-case-application-of-hif-phis-for-the-treatment-of-anemia-in-patients-with-ckd-f7al?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/case-by-case-application-of-hif-phis-for-the-treatment-of-anemia-in-patients-with-ckd-f7al?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/lxw9mjsz4juq-HTRS25_Hepatic_myCMEBanners_MyCME800x385.png) VideoThe Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria Sammy Saab, MD, MPH, AGAF, FACG, FAASLD; Vandana Khungar, MD, MSc; Christopher V. Almario, MD, MSHPM](https:\/\/www.gotoper.com\/courses\/the-role-of-the-multidisciplinary-care-team-in-the-diagnosis-and-management-of-acute-hepatic-porphyria-hc4e?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/the-role-of-the-multidisciplinary-care-team-in-the-diagnosis-and-management-of-acute-hepatic-porphyria-hc4e?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/lxw9mjsz4juq-HTRS25_Hepatic_myCMEBanners_MyCME800x385.png) VideoThe Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria Sammy Saab, MD, MPH, AGAF, FACG, FAASLD; Vandana Khungar, MD, MSc; Christopher V. Almario, MD, MSHPM](https:\/\/www.gotoper.com\/courses\/the-role-of-the-multidisciplinary-care-team-in-the-diagnosis-and-management-of-acute-hepatic-porphyria-hc4e?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/the-role-of-the-multidisciplinary-care-team-in-the-diagnosis-and-management-of-acute-hepatic-porphyria-hc4e?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/10izyuwnvl47-RRRetina_nAMD-DMEWinter25_TICatalog750x361.png) Video(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME David M. Brown, MD, FACS; Dilraj S. Grewal, MD](https:\/\/www.gotoper.com\/courses\/rapid-reviews-in-retina-emerging-updates-from-winter-2025-addressing-the-wealth-of-new-data-in-treatments-for-namd-and-dme?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/rapid-reviews-in-retina-emerging-updates-from-winter-2025-addressing-the-wealth-of-new-data-in-treatments-for-namd-and-dme?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/10izyuwnvl47-RRRetina_nAMD-DMEWinter25_TICatalog750x361.png) Video(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME David M. Brown, MD, FACS; Dilraj S. Grewal, MD](https:\/\/www.gotoper.com\/courses\/rapid-reviews-in-retina-emerging-updates-from-winter-2025-addressing-the-wealth-of-new-data-in-treatments-for-namd-and-dme?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/rapid-reviews-in-retina-emerging-updates-from-winter-2025-addressing-the-wealth-of-new-data-in-treatments-for-namd-and-dme?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![ Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/ri5iomf2n5nz-ASRS_XLRP_TICatalog750x3611.png) VideoLiving With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience Lejla Vajzovic, MD, FASRS; Ramiro Maldonado, MD](https:\/\/www.gotoper.com\/courses\/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![ Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/ri5iomf2n5nz-ASRS_XLRP_TICatalog750x3611.png) VideoLiving With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience Lejla Vajzovic, MD, FASRS; Ramiro Maldonado, MD](https:\/\/www.gotoper.com\/courses\/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/72fzug9uvzzu-MBCC25_ISS_PMCPC_WebBanners_TICatalog750x361.png) MultimediaCommunity Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC](https:\/\/www.gotoper.com\/courses\/community-practice-connections-optimizing-treatment-outcomes-and-preserving-fertility-in-premenopausal-hr-breast-cancer?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/community-practice-connections-optimizing-treatment-outcomes-and-preserving-fertility-in-premenopausal-hr-breast-cancer?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/igbn7kc13r9g-CCC25_nAMDDME_TICatalog750x3612x.png) Video(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation Veeral Sheth, MD, MBA, FASRS, FACS; Mark R. Barakat, MD, FASRS; Geeta Lalwani, MD; Xiao Yi Zhou, MD](https:\/\/www.gotoper.com\/courses\/collaborative-community-connections-mastering-the-management-of-namd-and-dme-through-therapeutic-innovation?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/collaborative-community-connections-mastering-the-management-of-namd-and-dme-through-therapeutic-innovation?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![ Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/ri5iomf2n5nz-ASRS_XLRP_TICatalog750x3611.png) VideoLiving With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience Lejla Vajzovic, MD, FASRS; Ramiro Maldonado, MD](https:\/\/www.gotoper.com\/courses\/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![ Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/ri5iomf2n5nz-ASRS_XLRP_TICatalog750x3611.png) VideoLiving With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience Lejla Vajzovic, MD, FASRS; Ramiro Maldonado, MD](https:\/\/www.gotoper.com\/courses\/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/igbn7kc13r9g-CCC25_nAMDDME_TICatalog750x3612x.png) Video(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation Veeral Sheth, MD, MBA, FASRS, FACS; Mark R. Barakat, MD, FASRS; Geeta Lalwani, MD; Xiao Yi Zhou, MD](https:\/\/www.gotoper.com\/courses\/collaborative-community-connections-mastering-the-management-of-namd-and-dme-through-therapeutic-innovation?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/collaborative-community-connections-mastering-the-management-of-namd-and-dme-through-therapeutic-innovation?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/8q4nbzp3xvdd-PERPodcastSeries_BTC_Pod2_TICatalog750x3612x.png) VideoFrom Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS](https:\/\/www.gotoper.com\/courses\/from-bench-to-bedside-paradigm-shifts-in-her2-metastatic-btc-treatment?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/from-bench-to-bedside-paradigm-shifts-in-her2-metastatic-btc-treatment?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Collaborative Care Symposium](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/sfdryshzuc1v-TICatalog750x3612x342.png) Virtual EventCollaborative Care Symposium May 2-3, 2026](https:\/\/www.gotoper.com\/courses\/collaborative-care-symposium?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/collaborative-care-symposium?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Proactive Adverse Event Management for HER2+ BTC Treatments](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/gcrqdi7eprzi-PER_PodSeries_BTC_Pod3_TICatalog750x3612x.png) VideoProactive Adverse Event Management for HER2+ BTC Treatments Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO](https:\/\/www.gotoper.com\/courses\/proactive-adverse-event-management-for-her2-btc-treatments?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/proactive-adverse-event-management-for-her2-btc-treatments?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/ndfh02xn9dzr-CRU25_ISS_Glaucoma_myCMEBanners_MyCME800x385.png) VideoNavigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge Deborah Ristvedt, DO; Melissa Tawa, OD, FAAO](https:\/\/www.gotoper.com\/courses\/navigating-the-glaucoma-therapeutic-and-surgical-landscape-from-conventional-to-cutting-edge?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/navigating-the-glaucoma-therapeutic-and-surgical-landscape-from-conventional-to-cutting-edge?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/m0tuj7iifza3-ONS25_Ovarian_TICatalog750x3612x1.png) VideoShow Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer Ritu Salani, MD, MBA; Jill Alldredge, MD; Emely Alfaro, MS, RN, CNS, OCN](https:\/\/www.gotoper.com\/courses\/show-me-your-care-plan-insights-for-oncology-nurses-integrating-recent-developments-to-improve-outcomes-for-patients-with-platinum-resistant-ovarian-cancer-elfw?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/show-me-your-care-plan-insights-for-oncology-nurses-integrating-recent-developments-to-improve-outcomes-for-patients-with-platinum-resistant-ovarian-cancer-elfw?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/sdlxwtp44t32-CRU25_ISS_NK_myCMEBanners_MyCME800x385.png) Video(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes Melissa Barnett, OD, FAAO, FSLS, FBCLA; Cecelia Koetting, OD, FAAO, DipABO; Quan Đông Nguyễn, MD, MSc; Jennifer Li, MD](https:\/\/www.gotoper.com\/courses\/neurotrophic-keratitis-multidisciplinary-approaches-to-enhance-patient-outcomes?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/neurotrophic-keratitis-multidisciplinary-approaches-to-enhance-patient-outcomes?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/sdlxwtp44t32-CRU25_ISS_NK_myCMEBanners_MyCME800x385.png) Video(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes Melissa Barnett, OD, FAAO, FSLS, FBCLA; Cecelia Koetting, OD, FAAO, DipABO; Quan Đông Nguyễn, MD, MSc; Jennifer Li, MD](https:\/\/www.gotoper.com\/courses\/neurotrophic-keratitis-multidisciplinary-approaches-to-enhance-patient-outcomes?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/neurotrophic-keratitis-multidisciplinary-approaches-to-enhance-patient-outcomes?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/qcag6duoxbzo-ACP25_CGM_TICatalog750x3612x1.png) VideoCases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-a-horizon-view-of-continuous-monitoring-systems-for-diabetes-management-n3wp?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-a-horizon-view-of-continuous-monitoring-systems-for-diabetes-management-n3wp?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Expert Illustrations and Commentaries™: Managing Hyperphosphatemia in CKD—A Closer Look at the Paracellular Pathway](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/y4ert3rtufci-ANNA25_CKD_TICatalog750x3612x1.png) VideoExpert Illustrations and Commentaries™: Managing Hyperphosphatemia in CKD—A Closer Look at the Paracellular Pathway Anil K. Agarwal, MD; Nissreen Elfadawy, MD, MS, FASN, FAST](https:\/\/www.gotoper.com\/courses\/expert-illustrations-and-commentaries-managing-hyperphosphatemia-in-ckda-closer-look-at-the-paracellular-pathway?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/expert-illustrations-and-commentaries-managing-hyperphosphatemia-in-ckda-closer-look-at-the-paracellular-pathway?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/ymqok2s4swdg-ASCRS25_TICatalog750x3612x2.png) Video(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management Marjan Farid, MD; John Hovanesian, MD; Beeran Meghpara, MD](https:\/\/www.gotoper.com\/courses\/the-neural-network-exploring-the-role-of-neuromodulation-in-dry-eye-disease-management-6q0a?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/the-neural-network-exploring-the-role-of-neuromodulation-in-dry-eye-disease-management-6q0a?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/ymqok2s4swdg-ASCRS25_TICatalog750x3612x2.png) Video(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management Marjan Farid, MD; John Hovanesian, MD; Beeran Meghpara, MD](https:\/\/www.gotoper.com\/courses\/the-neural-network-exploring-the-role-of-neuromodulation-in-dry-eye-disease-management-6q0a?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/the-neural-network-exploring-the-role-of-neuromodulation-in-dry-eye-disease-management-6q0a?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/rfr4hzmsgoxs-ASCRS25_IOLs_WebBanners_TICatalog750x361.png) Video(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success Tanner Ferguson, MD; Taj Nasser, MD, FWCRS](https:\/\/www.gotoper.com\/courses\/toric-iols-unleashed-from-technological-progress-to-patient-success?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/toric-iols-unleashed-from-technological-progress-to-patient-success?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/c1asofgfjc4q-MRLDMETICatalog750x361.png) Video(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR David A. Eichenbaum, MD](https:\/\/www.gotoper.com\/courses\/clinical-case-connections-understanding-the-impact-of-advances-in-treatment-for-dme-and-dr?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/clinical-case-connections-understanding-the-impact-of-advances-in-treatment-for-dme-and-dr?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/c1asofgfjc4q-MRLDMETICatalog750x361.png) Video(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR David A. Eichenbaum, MD](https:\/\/www.gotoper.com\/courses\/clinical-case-connections-understanding-the-impact-of-advances-in-treatment-for-dme-and-dr?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/clinical-case-connections-understanding-the-impact-of-advances-in-treatment-for-dme-and-dr?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/qqt1jbn4kcnm-MRLnAMDTICatalog750x361.png) Video(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD Nathan C. Steinle, MD](https:\/\/www.gotoper.com\/courses\/clinical-case-connections-expert-insights-on-applying-therapeutic-innovations-in-namd?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/clinical-case-connections-expert-insights-on-applying-therapeutic-innovations-in-namd?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/h0e1xgmkslph-TICatalog750x3612x87.png) AudioShow Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer Ritu Salani, MD, MBA; Emely Alfaro, MS, RN, CNS, OCN; Jill Alldredge, MD](https:\/\/www.gotoper.com\/courses\/show-me-your-care-plan-insights-for-oncology-nurses-integrating-recent-developments-to-improve-outcomes-for-patients-with-platinum-resistant-ovarian-cancer-0bs0?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/show-me-your-care-plan-insights-for-oncology-nurses-integrating-recent-developments-to-improve-outcomes-for-patients-with-platinum-resistant-ovarian-cancer-0bs0?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Cases and Conversations™: Improving Identification and Management of Patients with Congenital Adrenal Hyperplasia (CAH)](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/b75so9magft1-TICatalog750x3612x601.png) VideoCases and Conversations™: Improving Identification and Management of Patients with Congenital Adrenal Hyperplasia (CAH) Perrin C White, MD; Richard J. Auchus, MD, PhD; Mimi Kim, MD, MSc](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-improving-identification-and-management-of-patients-with-congenital-adrenal-hyperplasia-cah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-improving-identification-and-management-of-patients-with-congenital-adrenal-hyperplasia-cah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Cases and Conversations™: Improving Identification and Management of Patients with Congenital Adrenal Hyperplasia (CAH)](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/b75so9magft1-TICatalog750x3612x601.png) VideoCases and Conversations™: Improving Identification and Management of Patients with Congenital Adrenal Hyperplasia (CAH) Perrin C White, MD; Richard J. Auchus, MD, PhD; Mimi Kim, MD, MSc](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-improving-identification-and-management-of-patients-with-congenital-adrenal-hyperplasia-cah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-improving-identification-and-management-of-patients-with-congenital-adrenal-hyperplasia-cah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/qqt1jbn4kcnm-MRLnAMDTICatalog750x361.png) Video(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD Nathan C. Steinle, MD](https:\/\/www.gotoper.com\/courses\/clinical-case-connections-expert-insights-on-applying-therapeutic-innovations-in-namd?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/clinical-case-connections-expert-insights-on-applying-therapeutic-innovations-in-namd?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/rfr4hzmsgoxs-ASCRS25_IOLs_WebBanners_TICatalog750x361.png) Video(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success Tanner Ferguson, MD; Taj Nasser, MD, FWCRS](https:\/\/www.gotoper.com\/courses\/toric-iols-unleashed-from-technological-progress-to-patient-success?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/toric-iols-unleashed-from-technological-progress-to-patient-success?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/c667g7ip86ev-PERPodcastSeries_ALS_Pod1_WebBanners_TICatalog750x361.png) AudioPER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS) Richard Bedlack, MD, PhD](https:\/\/www.gotoper.com\/courses\/per-podcast-maximizing-the-multidisciplinary-care-outcomes-of-patients-with-amyotrophic-lateral-sclerosis-als?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/per-podcast-maximizing-the-multidisciplinary-care-outcomes-of-patients-with-amyotrophic-lateral-sclerosis-als?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/lfoy632hm4k3-PERPodcastSeries_ALS_Pod2_WebBanners_TICatalog750x361.png) AudioPER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS) Terry Heiman-Patterson, MD](https:\/\/www.gotoper.com\/courses\/per-podcast-best-strategies-for-approaching-the-diagnosis-of-amyotrophic-lateral-sclerosis-als?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/per-podcast-best-strategies-for-approaching-the-diagnosis-of-amyotrophic-lateral-sclerosis-als?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Expert Illustrations & Commentaries™: Visualizing the Role of the Complement Pathway in Paroxysmal Nocturnal Hemoglobinuria](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/zn7wbzsfllei-TICatalog750x3612x33.png) MultimediaExpert Illustrations & Commentaries™: Visualizing the Role of the Complement Pathway in Paroxysmal Nocturnal Hemoglobinuria Caroline Piatek, MD; Ilene Weitz, MD](https:\/\/www.gotoper.com\/courses\/expert-illustrations-commentaries-visualizing-the-role-of-the-complement-pathway-in-paroxysmal-nocturnal-hemoglobinuria?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/expert-illustrations-commentaries-visualizing-the-role-of-the-complement-pathway-in-paroxysmal-nocturnal-hemoglobinuria?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/bfifjatwf6ua-TICatalog750x3612x11.png) Video(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD](https:\/\/www.gotoper.com\/courses\/2025-cime-navigating-pharmacological-presbyopia-treatment-for-enhanced-patient-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/2025-cime-navigating-pharmacological-presbyopia-treatment-for-enhanced-patient-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/x9vh23n5lon9-TICatalog750x3612x641.png) VideoAddressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women Danielle Nance, MD; Kimberley Youkhana, MD](https:\/\/www.gotoper.com\/courses\/addressing-healthcare-inequities-detecting-and-managing-the-uncommon-hemophilia-in-women?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/addressing-healthcare-inequities-detecting-and-managing-the-uncommon-hemophilia-in-women?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/x9vh23n5lon9-TICatalog750x3612x641.png) VideoAddressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women Danielle Nance, MD; Kimberley Youkhana, MD](https:\/\/www.gotoper.com\/courses\/addressing-healthcare-inequities-detecting-and-managing-the-uncommon-hemophilia-in-women?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/addressing-healthcare-inequities-detecting-and-managing-the-uncommon-hemophilia-in-women?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/pnkrnaz3vky4-RADTSWTICatalog750x361.png) VideoUnderstanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD) Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD](https:\/\/www.gotoper.com\/courses\/understanding-topical-steroid-withdrawal-tsw-in-patients-with-atopic-dermatitis-ad-c78o?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/understanding-topical-steroid-withdrawal-tsw-in-patients-with-atopic-dermatitis-ad-c78o?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/bfifjatwf6ua-TICatalog750x3612x11.png) Video(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD](https:\/\/www.gotoper.com\/courses\/2025-cime-navigating-pharmacological-presbyopia-treatment-for-enhanced-patient-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/2025-cime-navigating-pharmacological-presbyopia-treatment-for-enhanced-patient-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/nq6bshrgre1r-TICatalog750x3612x701.png) VideoPER Postgame™: Updates from ANNA in the Management of IgA Nephropathy Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA](https:\/\/www.gotoper.com\/courses\/per-postgame-updates-in-the-management-of-iga-nephropathy?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/per-postgame-updates-in-the-management-of-iga-nephropathy?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/6mnsbnihwq2t-TICatalog750x3612x214.png) VideoNeurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; John Hovanesian, MD, FACS](https:\/\/www.gotoper.com\/courses\/neurotrophic-keratitis-insights-an-interactive-corneal-sensitivity-testing-workshop?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/neurotrophic-keratitis-insights-an-interactive-corneal-sensitivity-testing-workshop?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![SimulatEd™ in Hypercortisolism and Type 2 Diabetes: Identifying Patients with Hypercortisolism](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/6ybpjsyms0fo-TICatalog750x3612x2911.png) Case-based SimulationSimulatEd™ in Hypercortisolism and Type 2 Diabetes: Identifying Patients with Hypercortisolism Richard E. Pratley, MD; Matthew P. Gilbert, DO, MPH](https:\/\/www.gotoper.com\/courses\/simulated-in-hypercortisolism-and-type-2-diabetes-identifying-patients-with-hypercortisolism?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/simulated-in-hypercortisolism-and-type-2-diabetes-identifying-patients-with-hypercortisolism?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/h3ryntwhq63o-CIMEDemotexTICatalog750x3612x1.png) Video(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD](https:\/\/www.gotoper.com\/courses\/small-mites-big-impact-revolutionizing-demodex-blepharitis-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/small-mites-big-impact-revolutionizing-demodex-blepharitis-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/16d7ydt8wpt6-TICatalog750x3612x2321.png) VideoClinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc](https:\/\/www.gotoper.com\/courses\/clinical-consultations-providing-holistic-care-for-complex-cases-of-psoriasis-with-cardiovascular-comorbidities?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/clinical-consultations-providing-holistic-care-for-complex-cases-of-psoriasis-with-cardiovascular-comorbidities?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/16d7ydt8wpt6-TICatalog750x3612x2321.png) VideoClinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc](https:\/\/www.gotoper.com\/courses\/clinical-consultations-providing-holistic-care-for-complex-cases-of-psoriasis-with-cardiovascular-comorbidities?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/clinical-consultations-providing-holistic-care-for-complex-cases-of-psoriasis-with-cardiovascular-comorbidities?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care](https:\/\/d36ai2hkxl16us.cloudfront.net\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/h3ryntwhq63o-CIMEDemotexTICatalog750x3612x1.png) Video(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD](https:\/\/www.gotoper.com\/courses\/small-mites-big-impact-revolutionizing-demodex-blepharitis-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/small-mites-big-impact-revolutionizing-demodex-blepharitis-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed\/Refractory Multiple Myeloma](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/7wvhdmjbpzq3-ASCORRMMTICatalog750x3611.png) VideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed\/Refractory Multiple Myeloma C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-sorting-through-the-expanding-treatment-options-for-patients-with-relapsedrefractory-multiple-myeloma-wink?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-sorting-through-the-expanding-treatment-options-for-patients-with-relapsedrefractory-multiple-myeloma-wink?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/yghd89xssfic-ASCO25_ADCMBCTICatalog750x3611.png) VideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS](https:\/\/www.gotoper.com\/courses\/cases-conversations-transforming-aml-careprecision-strategies-evolving-therapies-and-clinical-insights-91pp?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/cases-conversations-transforming-aml-careprecision-strategies-evolving-therapies-and-clinical-insights-91pp?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/2bg381rlbfzn-ASCO25_MFPVTICatalog750x361.png) VideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD](https:\/\/www.gotoper.com\/courses\/medical-crossfire-improving-patient-outcomes-in-myeloproliferative-neoplasms-with-novel-therapeutic-approaches-1?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/medical-crossfire-improving-patient-outcomes-in-myeloproliferative-neoplasms-with-novel-therapeutic-approaches-1?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 1)](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/c1bwjcrftf7t-BurstCMEV3_CKDTITICatalog750x3611.png) MultimediaBurst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 1) Suneel Udani, MD](https:\/\/www.gotoper.com\/courses\/burst-cme-managing-fluid-overload-in-patients-with-chronic-kidney-disease?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/burst-cme-managing-fluid-overload-in-patients-with-chronic-kidney-disease?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![ Looking Beneath the Surface: Latest Updates in Identifying and Managing Hypercortisolism in Patients with Type 2 Diabetes](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/4xtdfqm5y16h-TICatalog750x3612x9.png) VideoLooking Beneath the Surface: Latest Updates in Identifying and Managing Hypercortisolism in Patients with Type 2 Diabetes Richard E. Pratley, MD; Vivian Fonseca, MD, FRCP](https:\/\/www.gotoper.com\/courses\/per-postgame-looking-beneath-the-surface-latest-updates-in-identifying-and-managing-hypercortisolism-in-patients-with-type-2-diabetes?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/per-postgame-looking-beneath-the-surface-latest-updates-in-identifying-and-managing-hypercortisolism-in-patients-with-type-2-diabetes?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/gd8dvx0r87tz-TICatalog750x3612x61.png) VideoNavigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management Andrew Alexis, MD, MPH; Leon Kircik, MD](https:\/\/www.gotoper.com\/courses\/navigating-safety-data-with-janus-kinase-jak-inhibitors-in-atopic-dermatitis-ad-management-et4u?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/navigating-safety-data-with-janus-kinase-jak-inhibitors-in-atopic-dermatitis-ad-management-et4u?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/0vkef67cs6nz-TICatalog750x3612x11.png) VideoRapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease SriniVas Sadda, MD, FARVO; Nathan Steinle, MD](https:\/\/www.gotoper.com\/courses\/rapid-reviews-in-retina-emerging-updates-from-spring-2025addressing-the-wealth-of-new-data-in-treatments-for-neovascular-retinal-disease?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/rapid-reviews-in-retina-emerging-updates-from-spring-2025addressing-the-wealth-of-new-data-in-treatments-for-neovascular-retinal-disease?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Interventional Dry Eye: A Stepwise Treatment & Management Approach](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/37zzqxcjm42r-AOADEDTICatalog750x3611.png) VideoInterventional Dry Eye: A Stepwise Treatment & Management Approach Mark Schaeffer, OD, FAAO; Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO, FAAOMS; Selina R. McGee, OD, FAAO](https:\/\/www.gotoper.com\/courses\/interventional-dry-eye-a-stepwise-treatment-and-management-approach?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/interventional-dry-eye-a-stepwise-treatment-and-management-approach?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/eqalj1ca37qk-TICatalog750x3612x51.png) VideoAssessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD](https:\/\/www.gotoper.com\/courses\/assessing-the-evidence-for-ox40-ox40l-axis-inhibition-for-the-treatment-of-atopic-dermatitis-eaxm?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/assessing-the-evidence-for-ox40-ox40l-axis-inhibition-for-the-treatment-of-atopic-dermatitis-eaxm?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 2)](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/c1bwjcrftf7t-BurstCMEV3_CKDTITICatalog750x3611.png) MultimediaBurst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 2) Suneel Udani, MD](https:\/\/www.gotoper.com\/courses\/burst-cme-managing-fluid-overload-in-patients-with-chronic-kidney-disease-part-2?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/burst-cme-managing-fluid-overload-in-patients-with-chronic-kidney-disease-part-2?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/ox6vub9txysu-TICatalog750x3612x71.png) VideoPatient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD](https:\/\/www.gotoper.com\/courses\/patient-provider-and-caregiver-connection-turning-a-new-leaf-in-acute-pain-management-how-recent-advancements-impact-the-treatment-paradigm?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/patient-provider-and-caregiver-connection-turning-a-new-leaf-in-acute-pain-management-how-recent-advancements-impact-the-treatment-paradigm?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/njdnnzcxsiim-ASRS_XLRP_WebBannersNEWTitle_ASRS_XLRP_TICatalog750x361.png) Video(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS](https:\/\/www.gotoper.com\/courses\/collaborating-across-the-continuum-best-practices-in-patient-centric-team-management-of-xlrp-0vbw?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/collaborating-across-the-continuum-best-practices-in-patient-centric-team-management-of-xlrp-0vbw?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/l0szys11gab0-eec7259e-fdaf-4450-8aa4-843267866004.jpg) MultimediaBurst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice Jerry Bagel, MD, MS](https:\/\/www.gotoper.com\/courses\/burst-cme-optimizing-care-for-patients-with-psoriasis-incorporating-a-buy-and-bill-model-for-biologic-agents-into-dermatological-practice?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/burst-cme-optimizing-care-for-patients-with-psoriasis-incorporating-a-buy-and-bill-model-for-biologic-agents-into-dermatological-practice?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/ouwd4qnjzqwf-ASRS_MacTel_TICatalog750x361.png) Video(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS](https:\/\/www.gotoper.com\/courses\/the-evolution-of-mactel-management-integrating-neuroprotective-therapies-into-clinical-practice-62lr?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/the-evolution-of-mactel-management-integrating-neuroprotective-therapies-into-clinical-practice-62lr?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![ Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/qsk84tt8r2ij-SOCALMDDTICatalog750x361.png) VideoLive Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C](https:\/\/www.gotoper.com\/courses\/2025-socal-psych-expert-illustrations-commentary-visualizing-novel-therapeutic-targets-for-patients-with-major-depressive-disorder?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/2025-socal-psych-expert-illustrations-commentary-visualizing-novel-therapeutic-targets-for-patients-with-major-depressive-disorder?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/ldpdqdf40tvd-RRR25_Summer_NRD_TICatalog750x3612x1.png) Video(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS](https:\/\/www.gotoper.com\/courses\/rapid-reviews-in-retina-emerging-updates-from-summer-2025addressing-the-wealth-of-new-data-in-treatments-for-neovascular-retinal-disease?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/rapid-reviews-in-retina-emerging-updates-from-summer-2025addressing-the-wealth-of-new-data-in-treatments-for-neovascular-retinal-disease?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/enj0a03s0y5z-ASRS25_NEW_WebBanners_Updated_ASRS25_VEG_TICatalog750x361.png) Video(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD](https:\/\/www.gotoper.com\/courses\/a-forward-look-at-anti-vegf-therapies-a-paradigm-shift-in-neovascular-retinal-disease-management?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/a-forward-look-at-anti-vegf-therapies-a-paradigm-shift-in-neovascular-retinal-disease-management?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/4zhg5jz1vvvi-TICatalog750x3613.png) VideoCases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-biologic-matchmaking-in-psoriasis-finding-the-right-therapy-for-the-right-patient-7tcu?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-biologic-matchmaking-in-psoriasis-finding-the-right-therapy-for-the-right-patient-7tcu?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/77r2aohwh5yi-TICatalog750x3612x58.png) VideoCollaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH Jean M. Elwing, MD, FCCP; Russel Hirsch, MD; John F. Morehous, MD](https:\/\/www.gotoper.com\/courses\/collaborating-across-the-continuum-the-pediatricians-vital-role-in-multidisciplinary-management-of-pediatric-pah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/collaborating-across-the-continuum-the-pediatricians-vital-role-in-multidisciplinary-management-of-pediatric-pah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/77r2aohwh5yi-TICatalog750x3612x58.png) VideoCollaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH Jean M. Elwing, MD, FCCP; Russel Hirsch, MD; John F. Morehous, MD](https:\/\/www.gotoper.com\/courses\/collaborating-across-the-continuum-the-pediatricians-vital-role-in-multidisciplinary-management-of-pediatric-pah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/collaborating-across-the-continuum-the-pediatricians-vital-role-in-multidisciplinary-management-of-pediatric-pah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/77r2aohwh5yi-TICatalog750x3612x58.png) VideoCollaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH Jean M. Elwing, MD, FCCP; Russel Hirsch, MD; John F. Morehous, MD](https:\/\/www.gotoper.com\/courses\/collaborating-across-the-continuum-the-pediatricians-vital-role-in-multidisciplinary-management-of-pediatric-pah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/collaborating-across-the-continuum-the-pediatricians-vital-role-in-multidisciplinary-management-of-pediatric-pah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/yipisaym6igm-PPCC25_Vitiligo_WebBannersV2_PPCC25_Viti_TICatalog750x3611.png) VideoPatient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD](https:\/\/www.gotoper.com\/courses\/patient-provider-and-caregiver-connection-addressing-patient-challenges-with-holistic-approaches-to-vitiligo-management?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/patient-provider-and-caregiver-connection-addressing-patient-challenges-with-holistic-approaches-to-vitiligo-management?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/3ru5xlnlioem-CCC_Neovascular_TICatalog750x3611.png) Video(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD](https:\/\/www.gotoper.com\/courses\/community-collaborative-connections-optimizing-the-collaborative-care-of-neovascular-retinal-disease-in-a-new-age-of-treatment?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/community-collaborative-connections-optimizing-the-collaborative-care-of-neovascular-retinal-disease-in-a-new-age-of-treatment?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/mcyybmt7s0c5-SOCALSchizophreniaTICatalog750x361.png) Video(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia Gus Alva, MD, DFAPA; Ilan Melnick, MD](https:\/\/www.gotoper.com\/courses\/overcoming-barriers-to-long-acting-injectable-agents-in-schizophrenia?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/overcoming-barriers-to-long-acting-injectable-agents-in-schizophrenia?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/gbcbgzzruahm-CxC25_HeartFailure_TICatalog750x3612x.png) VideoCases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence Edgar V. Lerma, MD; Anuradha Lala-Trindade, MD](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-mineralocorticoid-receptor-antagonists-in-patients-with-hfaugmenting-current-guidelines-with-emerging-evidence?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-mineralocorticoid-receptor-antagonists-in-patients-with-hfaugmenting-current-guidelines-with-emerging-evidence?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/qwthl1m8frlz-SSM26_HS_TICatalog750x3612x1.png) VideoHidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches Hadar Lev-Tov, MD; Martina Porter, MD](https:\/\/www.gotoper.com\/courses\/hidradenitis-suppurativa-diving-deeper-into-disease-pathogenesis-severity-assessment-and-holistic-management-approaches?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/hidradenitis-suppurativa-diving-deeper-into-disease-pathogenesis-severity-assessment-and-holistic-management-approaches?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/sy1pxc8q7s1i-BurstCME25_Glucose_WebBanners_BurstCME25_TICatalog750x36111.png) VideoBurst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients Jennifer Green, MD; Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP](https:\/\/www.gotoper.com\/courses\/burst-cme-cgm-continuous-glucose-monitoring-considerations-maximizing-quality-of-life-for-patients?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/burst-cme-cgm-continuous-glucose-monitoring-considerations-maximizing-quality-of-life-for-patients?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[![ Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update](https:\/\/media.thoughtindustries.com\/thoughtindustries\/image\/upload\/v1\/course-uploads\/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0\/tp7povica5jm-CACHyperlipidemiaTICatalog750x361.png) VideoProgress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-progress-in-hyperlipidemia-management-to-reduce-ascvd-risk-an-illustrated-update?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\n[View more](https:\/\/www.gotoper.com\/courses\/cases-and-conversations-progress-in-hyperlipidemia-management-to-reduce-ascvd-risk-an-illustrated-update?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck)\n\nPrevious slide\n\nNext slide\n\nAdvertisement\n\nAdvertisement\n\n## Trending on HCPLive\n[1FDA Approves Sparsentan for Focal Segmental Glomerulosclerosis](https:\/\/www.hcplive.com\/view\/fda-approves-sparsentan-for-focal-segmental-glomerulosclerosis)\n\n[2Why Sparsentan’s FDA Approval Marks a Turning Point in FSGS, With Howard Tratchman, MD](https:\/\/www.hcplive.com\/view\/why-sparsentan-fda-approval-marks-a-turning-point-in-fsgs-with-howard-tratchman-md)\n\n[3Brensocatib Phase 2b Study in HS Does Not Meet Endpoints, Program Discontinued](https:\/\/www.hcplive.com\/view\/brensocatib-phase-2b-study-hs-does-not-meet-endpoints-program-discontinued)\n\n[4Socioeconomic Pressures and Clinical Gains in Heart Disease, With Suyog Mokashi, MD](https:\/\/www.hcplive.com\/view\/socioeconomic-pressures-and-clinical-gains-in-heart-disease-with-suyog-mokashi-md)\n\n[5The Early-Life Window: Can Food Allergy Be Prevented Before It Begins?](https:\/\/www.hcplive.com\/view\/early-life-window-can-food-allergy-prevented-before-begins-)\n\n- [About Us](https:\/\/www.hcplive.com\/about)\n- [Advertise](https:\/\/www.hcplive.com\/advertise)\n- [Editorial](https:\/\/www.hcplive.com\/editorial)\n- [Contact Us](https:\/\/www.hcplive.com\/contact-us)\n- [Do Not Sell My Information](https:\/\/www.mjhlifesciences.com\/ccpa?domain=www.hcplive.com)\n- [Privacy](https:\/\/www.hcplive.com\/privacy)\n- [Terms & Conditions](https:\/\/www.hcplive.com\/terms)\n- Cookie settings\n\nContact Info\n\n259 Prospect Plains Rd, Bldg H  \n Cranbury, NJ 08512\n\n- [![Contagion Live](https:\/\/www.hcplive.com\/PartnerLogos\/contagionLive_white.png)](https:\/\/www.contagionlive.com\/)\n- [![CGT Live](https:\/\/www.hcplive.com\/PartnerLogos\/CGT_KO_NoTag.png)](https:\/\/www.cgtlive.com\/)\n- [![Neurology Live](https:\/\/www.hcplive.com\/PartnerLogos\/Neuro_white.png)](https:\/\/www.neurologylive.com\/)\n- [![HCP Live](https:\/\/www.hcplive.com\/PartnerLogos\/HCPlive_white.png)](https:\/\/www.hcplive.com\/)\n- [![Oncology Live](https:\/\/www.hcplive.com\/PartnerLogos\/OncLive_white.png)](https:\/\/www.onclive.com\/)\n- [![Contemporary Pediatrics](https:\/\/www.hcplive.com\/PartnerLogos\/contemporary_pediatrics_inverted_logo.png)](https:\/\/www.contemporarypediatrics.com\/)\n- [![Contemporary OBGYN](https:\/\/www.hcplive.com\/PartnerLogos\/contemporaryobgyn_inverted_logo.png)](https:\/\/www.contemporaryobgyn.net\/)\n- [![Urology Times](https:\/\/www.hcplive.com\/PartnerLogos\/ut_logo_white.png)](https:\/\/www.urologytimes.com\/)\n- [![The Educated Patient](https:\/\/www.hcplive.com\/PartnerLogos\/EP_Logo.png)](https:\/\/www.theeducatedpatient.com\/)\n- [![Patient Care Online](https:\/\/www.hcplive.com\/PartnerLogos\/PatientCare_white.png)](https:\/\/www.patientcareonline.com\/)\n\n![HCP Live Network](https:\/\/www.hcplive.com\/PartnerLogos\/hcplive_networkKO.png)\n\n![Brand Logo](https:\/\/www.hcplive.com\/an_mjhls_brand_ko.webp)\n\n© 2026 MJH Life Sciences®\n\nAll rights reserved.\n\n[Home](https:\/\/www.hcplive.com\/)\n\n[About Us](https:\/\/www.hcplive.com\/about-us)\n\n[News](https:\/\/www.hcplive.com\/news)\n\n[Contact Us](https:\/\/www.hcplive.com\/contact-us)","attrs_readable_markdown":"Although alternative medicine is a good compliment to conventional medical treatment, Steve Jobs' sole reliance on alternative medicine treatment may be the primary factor for his untimely death.\n\n![](https:\/\/cdn.sanity.io\/images\/0vv8moc6\/hcplive\/5f9cfbc7d54755c137d9c53fe0ce60044356bfb4-300x150.jpg?w=300&max-h=150&fit=crop&auto=format)\n\n![](https:\/\/cdn.sanity.io\/images\/0vv8moc6\/hcplive\/5f9cfbc7d54755c137d9c53fe0ce60044356bfb4-300x150.jpg?fit=crop&auto=format)\n\nWhen doctors first discovered the tumor in his pancreas in 2003, Steve Jobs was told that, with immediate surgery, the tumor could be removed and he had a high possibility of being cured. Instead, the co-founder of Apple declined the surgery and focused on using alternative medicine to treat his disease. Harvard medical school researcher, Dr. Ramzi Amri, referred to Jobs’ death at age 56, “unnecessarily early” due to his reliance on alternative medicine.\n\nAmri argued that Jobs reduced his chances of survival by resisting his doctors’ recommendations of immediate surgery after the 2003 diagnosis. “Given the circumstances it seems sound to assume that Mr. Jobs’ choice for alternative medicine could have led to an unnecessarily early death.” He added that based on his own research and other sources from biomedical research, the neuroendocrine tumor that Jobs was diagnosed with could have been cured had it not been for his decision to try alternative medicine.\n\n[Steve Jobs' Trust in Alternative Medicine Likely Shortened His Life, Researcher Contends](http:\/\/articles.nydailynews.com\/2011-10-14\/news\/30293918_1_alternative-medicine-pancreatic-cancer-neuroendocrine-tumor) **\\[New York Daily News\\]**\n\nAfter nine months of undergoing alternative medicine treatments for his disease, Jobs decided to allow for the use of conventional medicine in July 2004 due to the size of his tumor increasing. Jobs practiced Buddhism and was reportedly skeptical about mainstream medicine, instead stubbornly believing in unconventional methods to cure his ailments. Still, Dr. Jeffrey A. Norton, chief of surgical oncology at Stanford University, stated, “surgery is the only treatment modality that can result in a cure.” Norton was the one who removed Jobs’ tumor but alternative forms of treatment, such as a specialized diet and different meditation exercises, could have ultimately cost Jobs his life.\n\nBuddhist theories of medicine point to “three poisons” that cause people to get sick: greed, anger, and ignorance. Yet, why would a man who is so technologically-savvy as Steve Jobs be basing such important health decisions on ancient philosophies and natural remedies, especially when there have recently been more breakthroughs in cancer research than at any other point in history?\n\n[Did \"Alternative Medicine\" Kill Steve Jobs?](http:\/\/www.celebritydiagnosis.com\/2011\/10\/did-alternative-medicine-kill-steve-jobs\/) **\\[CelebrityDiagnosis.com\\]**\n\nIn terms of his alternative medicine treatments, it is still not known what exactly Jobs did to treat his cancer. He did reportedly restrict his diet to only fruits or fruits and vegetables, consulted psychics, and tried a procedure known as hydrotherapy. Surgical removal of the tumor for patients whose disease is detected while it is still confined to the pancreas, have a five-year survival rate of 87 percent. Thus, the majority of patients live for quite a while.\n\nIt is impossible to know whether surgery would have cured Jobs of his disease but his alternative medicine techniques, like acupuncture, were “not enough to change the course of the disease,” says Dr. Lowell Kobrin, a medical doctor who now focuses on acupuncture and herbal medicine at Northbend Medical Center in Coos Bay, Oregon. Kobrin added that the therapy could not affect cancer itself. Tim Birdsall, vice president of integrative medicine at the Cancer Treatment Centers of America, stated, “Once a cancer is established, in the vast majority of cases, simply changing the environment will not be sufficient to eradicate that established tumor.” While alternative medicine seems to be a beneficial compliment to conventional medicine, it cannot replace conventional medicine when trying to cure a dangerous disease.\n\n[Did Alternative Medicine Extend or Abbreviate Steve Jobs' Life?](http:\/\/www.scientificamerican.com\/article.cfm?id=alternative-medicine-extend-abbreviate-steve-jobs-life&page=3) **\\[Scientific American\\]**\n\nDue to Jobs’ form of pancreatic cancer being less lethal that the most common form of pancreatic cancer known as adenocarcinoma, many experts believe that his decision to wait before opting for surgery was not necessarily a bad idea. Julie Fleshman, president and chief executive officer of the Pancreatic Cancer Action Network, said that patients in Jobs’ situation don’t automatically have to rush treatment. “The length of time before you have to make a decision about your treatment is not as quick as someone whose been diagnosed with an adenocarcinoma,” she added.\n\nDr. Maged Rizk, a gastroenterologist at Cleveland Clinic, believed that Jobs waiting nine months for surgery was a bad decision. She said, “if it is an islet-cell tumor and the cells are \\[typical of early cancer\\], and as long as you don’t have symptoms, you can sit on it a bit.” Still, both Fleshman and Rizk agreed that alternative medicine treatments should not have been the sole methods of treatment for his disease.\n\n[Did Alternative Medicine Kill Steve Jobs?](http:\/\/www.livescience.com\/16551-steve-jobs-alternative-medicine-pancreatic-cancer-treatment.html) **\\[LiveScience.com\\]**\n\nWith the general consensus of medical experts being against the singular use of alternative medicine without conventional treatment, Steve Jobs agreed with them toward the end. Walter Isaacson, whose much-anticipated authorized biography on Jobs’ life is was released earlier this month, said that, before he died, the 56-year old Jobs had come to realize the mistake he made regarding his treatment. Isaacson said Jobs “wanted to talk about it, how he regretted it. I think he felt he should have been operated on \\[it\\] sooner.”\n\nJobs was pushed to embrace conventional medicine by many confidants, including his sister, Mona Simpson, and Art Levinson, an Apple board member. In the end, Jobs realized the mistake he made and regretted the decision he made to fight the disease that plagued him for so many years.\n\n[Steve Jobs 'Regretted Trying to Beat Cancer with Alternative Medicine for So Long'](http:\/\/www.telegraph.co.uk\/technology\/apple\/8841347\/Steve-Jobs-regretted-trying-to-beat-cancer-with-alternative-medicine-for-so-long.html) **\\[The Telegraph\\]**\n\n### Newsletter\nJoin thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.","meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

📄

INDEXABLE

✅

CRAWLED

1 day ago

🤖

ROBOTS ALLOWED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	PASS	`download_stamp > now() - 6 MONTH`	0.1 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	https://www.hcplive.com/view/is-alternative-medicine-to-blame-for-the-death-of-steve-jobs
Last Crawled	2026-04-15 11:20:49 (1 day ago)
First Indexed	2022-12-01 05:02:22 (3 years ago)
HTTP Status Code	200
Meta Title	Is Alternative Medicine to Blame for the Death of Steve Jobs? \| HCPLive
Meta Description	Although alternative medicine is a good compliment to conventional medical treatment, Steve Jobs' sole reliance on alternative medicine treatment may be the primary factor for his untimely death.
Meta Canonical	null
Boilerpipe Text	Although alternative medicine is a good compliment to conventional medical treatment, Steve Jobs' sole reliance on alternative medicine treatment may be the primary factor for his untimely death. When doctors first discovered the tumor in his pancreas in 2003, Steve Jobs was told that, with immediate surgery, the tumor could be removed and he had a high possibility of being cured. Instead, the co-founder of Apple declined the surgery and focused on using alternative medicine to treat his disease. Harvard medical school researcher, Dr. Ramzi Amri, referred to Jobs’ death at age 56, “unnecessarily early” due to his reliance on alternative medicine. Amri argued that Jobs reduced his chances of survival by resisting his doctors’ recommendations of immediate surgery after the 2003 diagnosis. “Given the circumstances it seems sound to assume that Mr. Jobs’ choice for alternative medicine could have led to an unnecessarily early death.” He added that based on his own research and other sources from biomedical research, the neuroendocrine tumor that Jobs was diagnosed with could have been cured had it not been for his decision to try alternative medicine. Steve Jobs' Trust in Alternative Medicine Likely Shortened His Life, Researcher Contends [New York Daily News] After nine months of undergoing alternative medicine treatments for his disease, Jobs decided to allow for the use of conventional medicine in July 2004 due to the size of his tumor increasing. Jobs practiced Buddhism and was reportedly skeptical about mainstream medicine, instead stubbornly believing in unconventional methods to cure his ailments. Still, Dr. Jeffrey A. Norton, chief of surgical oncology at Stanford University, stated, “surgery is the only treatment modality that can result in a cure.” Norton was the one who removed Jobs’ tumor but alternative forms of treatment, such as a specialized diet and different meditation exercises, could have ultimately cost Jobs his life. Buddhist theories of medicine point to “three poisons” that cause people to get sick: greed, anger, and ignorance. Yet, why would a man who is so technologically-savvy as Steve Jobs be basing such important health decisions on ancient philosophies and natural remedies, especially when there have recently been more breakthroughs in cancer research than at any other point in history? Did "Alternative Medicine" Kill Steve Jobs? [CelebrityDiagnosis.com] In terms of his alternative medicine treatments, it is still not known what exactly Jobs did to treat his cancer. He did reportedly restrict his diet to only fruits or fruits and vegetables, consulted psychics, and tried a procedure known as hydrotherapy. Surgical removal of the tumor for patients whose disease is detected while it is still confined to the pancreas, have a five-year survival rate of 87 percent. Thus, the majority of patients live for quite a while. It is impossible to know whether surgery would have cured Jobs of his disease but his alternative medicine techniques, like acupuncture, were “not enough to change the course of the disease,” says Dr. Lowell Kobrin, a medical doctor who now focuses on acupuncture and herbal medicine at Northbend Medical Center in Coos Bay, Oregon. Kobrin added that the therapy could not affect cancer itself. Tim Birdsall, vice president of integrative medicine at the Cancer Treatment Centers of America, stated, “Once a cancer is established, in the vast majority of cases, simply changing the environment will not be sufficient to eradicate that established tumor.” While alternative medicine seems to be a beneficial compliment to conventional medicine, it cannot replace conventional medicine when trying to cure a dangerous disease. Did Alternative Medicine Extend or Abbreviate Steve Jobs' Life? [Scientific American] Due to Jobs’ form of pancreatic cancer being less lethal that the most common form of pancreatic cancer known as adenocarcinoma, many experts believe that his decision to wait before opting for surgery was not necessarily a bad idea. Julie Fleshman, president and chief executive officer of the Pancreatic Cancer Action Network, said that patients in Jobs’ situation don’t automatically have to rush treatment. “The length of time before you have to make a decision about your treatment is not as quick as someone whose been diagnosed with an adenocarcinoma,” she added. Dr. Maged Rizk, a gastroenterologist at Cleveland Clinic, believed that Jobs waiting nine months for surgery was a bad decision. She said, “if it is an islet-cell tumor and the cells are [typical of early cancer], and as long as you don’t have symptoms, you can sit on it a bit.” Still, both Fleshman and Rizk agreed that alternative medicine treatments should not have been the sole methods of treatment for his disease. Did Alternative Medicine Kill Steve Jobs? [LiveScience.com] With the general consensus of medical experts being against the singular use of alternative medicine without conventional treatment, Steve Jobs agreed with them toward the end. Walter Isaacson, whose much-anticipated authorized biography on Jobs’ life is was released earlier this month, said that, before he died, the 56-year old Jobs had come to realize the mistake he made regarding his treatment. Isaacson said Jobs “wanted to talk about it, how he regretted it. I think he felt he should have been operated on [it] sooner.” Jobs was pushed to embrace conventional medicine by many confidants, including his sister, Mona Simpson, and Art Levinson, an Apple board member. In the end, Jobs realized the mistake he made and regretted the decision he made to fight the disease that plagued him for so many years. Steve Jobs 'Regretted Trying to Beat Cancer with Alternative Medicine for So Long' [The Telegraph] Newsletter Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.
Markdown	[![](https://www.hcplive.com/logo.webp)](https://www.hcplive.com/) [News](https://www.hcplive.com/news) Media [Clinical Forum Insights](https://www.hcplive.com/clinical-forum-insights)[Podcasts](https://www.hcplive.com/podcasts)[Shorts](https://www.hcplive.com/shorts)[State Of Sciences - Presentations](https://www.hcplive.com/state-of-sciences-presentations)[Videos](https://www.hcplive.com/videos)[Webinars](https://www.hcplive.com/webinars) Multimedia Series [CURE Connections®](https://www.hcplive.com/cure-connections)[Insights](https://www.hcplive.com/insights)[Medcast](https://www.hcplive.com/medcast)[Peer Exchange](https://www.hcplive.com/peer-exchange)[Peers & Perspectives](https://www.hcplive.com/peers-and-perspective)[Special Report](https://www.hcplive.com/special-report) Conferences [Conference Coverage](https://www.hcplive.com/latest-conference)[Conference Listing](https://www.hcplive.com/conference) More [Partners](https://www.hcplive.com/sap-partner) [CME/CE](https://www.hcplive.com/continuing-education) Resources [Digital Supplements](https://www.hcplive.com/journals/supplements/digital-supplement)[Interactive Tools](https://www.hcplive.com/interactive-tools)[Live Events](https://www.hcplive.com/events)[Press Release](https://www.hcplive.com/press-release)[Publications](https://www.hcplive.com/journals)[Sponsored](https://www.hcplive.com/sponsored) [Advisory Board](https://www.hcplive.com/advisory-board) [Subscribe](https://www.hcplive.com/subscribe) My Account - [News](https://www.hcplive.com/news) - Media - Multimedia Series - Conferences - [Partners](https://www.hcplive.com/sap-partner) - [CME/CE](https://www.hcplive.com/continuing-education) - Resources - [Advisory Board](https://www.hcplive.com/advisory-board) - [Subscribe](https://www.hcplive.com/subscribe) - [Allergy](https://www.hcplive.com/clinical/allergy) - [Seasonal Allergy](https://www.hcplive.com/clinical/seasonal-allergy) - [Food Allergy](https://www.hcplive.com/clinical/food-allergy) - [Anaphylaxis](https://www.hcplive.com/clinical/anaphylaxis) - [Biosimilars](https://www.hcplive.com/clinical/biosimilars) - [Cardiology](https://www.hcplive.com/clinical/cardiology) - [Dyslipidemia](https://www.hcplive.com/clinical/dyslipidemia) - [Arrhythmia](https://www.hcplive.com/clinical/arrhythmia) - [Cardiomyopathy](https://www.hcplive.com/clinical/cardiomyopathy) - [Structural Heart Disease](https://www.hcplive.com/clinical/structural-heart-disease) - [Atherosclerotic Cardiovascular Disease](https://www.hcplive.com/clinical/atherosclerotic-cardiovascular-disease) - [Heart Failure](https://www.hcplive.com/clinical/heart-failure) - [Hypertension](https://www.hcplive.com/clinical/hypertension) - [Stroke](https://www.hcplive.com/clinical/stroke) - [Venous Thromboembolism](https://www.hcplive.com/clinical/vte) - [Dermatology](https://www.hcplive.com/clinical/dermatology) - [Alopecia](https://www.hcplive.com/clinical/alopecia) - [Vitiligo](https://www.hcplive.com/clinical/vitiligo) - [Hidradenitis Suppurativa](https://www.hcplive.com/clinical/hidradenitis-suppurativa) - [Acne](https://www.hcplive.com/clinical/acne) - [Atopic Dermatitis](https://www.hcplive.com/clinical/atopic-dermatitis) - [Urticaria](https://www.hcplive.com/clinical/chronic-idiopathic-urticaria) - [Plaque Psoriasis](https://www.hcplive.com/clinical/plaque-psoriasis) - [Rosacea](https://www.hcplive.com/clinical/rosacea) - [Endocrinology](https://www.hcplive.com/clinical/endocrinology) - [Type 2 Diabetes](https://www.hcplive.com/clinical/type-2-diabetes) - [Type 1 Diabetes](https://www.hcplive.com/clinical/type-1-diabetes) - [Polycystic Ovary Syndrome](https://www.hcplive.com/clinical/polycystic-ovary-syndrome) - [Hormonal Disorders](https://www.hcplive.com/clinical/hormonal-disorders) - [Thyroid Disorders](https://www.hcplive.com/clinical/thyroid-disorders) - [FDA News](https://www.hcplive.com/clinical/fda-news) - [Family Medicine](https://www.hcplive.com/clinical/family-medicine) - [Influenza](https://www.hcplive.com/clinical/influenza) - [Vaccination](https://www.hcplive.com/clinical/vaccination) - [Gastroenterology](https://www.hcplive.com/clinical/gastroenterology) - [Exocrine Pancreatic Insufficiency](https://www.hcplive.com/clinical/exocrine-pancreatic-insufficiency) - [Inflammatory Bowel Disease](https://www.hcplive.com/clinical/ibd) - [C Difficile Infection](https://www.hcplive.com/clinical/c-difficile-resources) - [Gastroesophageal Reflux Disease (GERD)](https://www.hcplive.com/clinical/gastroesophageal-reflux-disease) - [Irritable Bowel Syndrome](https://www.hcplive.com/clinical/irritable-bowel-syndrome) - [Peptic Ulcer](https://www.hcplive.com/clinical/peptic-ulcer) - [Ulcerative Colitis](https://www.hcplive.com/clinical/ulcerative-colitis) - [Geriatrics](https://www.hcplive.com/clinical/geriatrics) - [Dementia and Alzheimer Disease](https://www.hcplive.com/clinical/alzheimer-disease) - [Parkinson Disease](https://www.hcplive.com/clinical/parkinsons-disease) - [Hematology](https://www.hcplive.com/clinical/hematology) - [Paroxysmal Nocturnal Hemoglobinuria](https://www.hcplive.com/clinical/paroxysmal-nocturnal-hemoglobinuria) - [Anemia](https://www.hcplive.com/clinical/anemia) - [Sickle Cell](https://www.hcplive.com/clinical/sickle-cell) - [Hepatology](https://www.hcplive.com/clinical/hepatology) - [Alpha-1 antitrypsin deficiency](https://www.hcplive.com/clinical/aatd) - [Cholangitis](https://www.hcplive.com/clinical/cholangitis) - [MASH / MASLD](https://www.hcplive.com/clinical/mash-masld) - [Hepatitis C](https://www.hcplive.com/clinical/hepatitis-c) - [Hospital Medicine](https://www.hcplive.com/clinical/hospital-medicine) - [Infectious Disease](https://www.hcplive.com/clinical/infectious-disease) - [COVID-19](https://www.hcplive.com/clinical/coronavirus) - [HIV/AIDS](https://www.hcplive.com/clinical/hiv-aids) - [Internal Medicine](https://www.hcplive.com/clinical/internal-medicine) - [Nephrology](https://www.hcplive.com/clinical/nephrology) - [C3 Glomerulopathy](https://www.hcplive.com/clinical/c3-glomerulopathy) - [IgA Nephropathy](https://www.hcplive.com/clinical/berger-disease) - [Focal Segmental Glomerulosclerosis](https://www.hcplive.com/clinical/focal-segmental-glomerulosclerosis) - [Chronic Kidney Disease](https://www.hcplive.com/clinical/chronic-kidney-disease) - [Neurology](https://www.hcplive.com/clinical/neurology) - [Epilepsy](https://www.hcplive.com/clinical/epilepsy) - [Migraine](https://www.hcplive.com/clinical/migraine) - [Tardive Dyskinesia](https://www.hcplive.com/clinical/tardive-dyskinesia) - [Traumatic Brain Injury](https://www.hcplive.com/clinical/tbi) - [Obesity Management](https://www.hcplive.com/clinical/obesity-management) - [Ophthalmology](https://www.hcplive.com/clinical/ophthalmology) - [Geographic Atrophy](https://www.hcplive.com/clinical/geographic-atrophy) - [Age-Related Macular Degeneration](https://www.hcplive.com/clinical/amd) - [Diabetic Macular Edema](https://www.hcplive.com/clinical/diabetic-macular-edema) - [Uveitis](https://www.hcplive.com/clinical/uveitis) - [Pain](https://www.hcplive.com/clinical/pain) - [Acute Pain](https://www.hcplive.com/clinical/acute-pain) - [Chronic Pain](https://www.hcplive.com/clinical/chronic-pain) - [Multiple Sclerosis](https://www.hcplive.com/clinical/multiple-sclerosis) - [Neuropathic Pain](https://www.hcplive.com/clinical/neuropathic-pain) - [Pediatrics](https://www.hcplive.com/clinical/pediatrics) - [Psychiatry](https://www.hcplive.com/clinical/psychiatry) - [PTSD](https://www.hcplive.com/clinical/ptsd) - [Addiction](https://www.hcplive.com/clinical/addiction) - [ADHD](https://www.hcplive.com/clinical/adhd) - [Bipolar Disorder](https://www.hcplive.com/clinical/bipolar-disorder) - [Major Depressive Disorder](https://www.hcplive.com/clinical/major-depressive-disorder) - [Schizophrenia](https://www.hcplive.com/clinical/schizophrenia) - [Pulmonology](https://www.hcplive.com/clinical/pulmonology) - [Lung Cancer](https://www.hcplive.com/clinical/lung-cancer) - [Pulmonary Fibrosis](https://www.hcplive.com/clinical/pulmonary-fibrosis) - [Asthma](https://www.hcplive.com/clinical/asthma) - [COPD](https://www.hcplive.com/clinical/copd) - [RDR Alert®](https://www.hcplive.com/clinical/rare-diseases) - [Vasculitis](https://www.hcplive.com/clinical/vasculitis) - [Amyloidosis](https://www.hcplive.com/clinical/amyloidosis) - [Huntington Disease](https://www.hcplive.com/clinical/huntington-disease) - [Lysosomal Storage Disorders](https://www.hcplive.com/clinical/lysosomal-storage-disorders) - [Rheumatology](https://www.hcplive.com/clinical/rheumatology) - [Sleep](https://www.hcplive.com/clinical/sleep) - [Obstructive Sleep Apnea](https://www.hcplive.com/clinical/obstructive-sleep-apnea) - [Insomnia](https://www.hcplive.com/clinical/insomnia) - [Surgery](https://www.hcplive.com/clinical/surgery) - [Plastic surgery](https://www.hcplive.com/clinical/plastic-surgery) - [Women's Health](https://www.hcplive.com/clinical/womens-health) Choose Specialty Spotlight - [FDA News](https://www.hcplive.com/clinical/fda-news)\\| [This Year In Medicine 2025](https://www.hcplive.com/this-year-in-medicine) Advertisement \\|Articles\\|October 31, 2011 # Is Alternative Medicine to Blame for the Death of Steve Jobs? Author(s)[Will Bonesso](https://www.hcplive.com/authors/will-bonesso) Although alternative medicine is a good compliment to conventional medical treatment, Steve Jobs' sole reliance on alternative medicine treatment may be the primary factor for his untimely death. Advertisement ![](https://cdn.sanity.io/images/0vv8moc6/hcplive/5f9cfbc7d54755c137d9c53fe0ce60044356bfb4-300x150.jpg?w=300&max-h=150&fit=crop&auto=format) ![](https://cdn.sanity.io/images/0vv8moc6/hcplive/5f9cfbc7d54755c137d9c53fe0ce60044356bfb4-300x150.jpg?fit=crop&auto=format) When doctors first discovered the tumor in his pancreas in 2003, Steve Jobs was told that, with immediate surgery, the tumor could be removed and he had a high possibility of being cured. Instead, the co-founder of Apple declined the surgery and focused on using alternative medicine to treat his disease. Harvard medical school researcher, Dr. Ramzi Amri, referred to Jobs’ death at age 56, “unnecessarily early” due to his reliance on alternative medicine. Amri argued that Jobs reduced his chances of survival by resisting his doctors’ recommendations of immediate surgery after the 2003 diagnosis. “Given the circumstances it seems sound to assume that Mr. Jobs’ choice for alternative medicine could have led to an unnecessarily early death.” He added that based on his own research and other sources from biomedical research, the neuroendocrine tumor that Jobs was diagnosed with could have been cured had it not been for his decision to try alternative medicine. [Steve Jobs' Trust in Alternative Medicine Likely Shortened His Life, Researcher Contends](http://articles.nydailynews.com/2011-10-14/news/30293918_1_alternative-medicine-pancreatic-cancer-neuroendocrine-tumor) \[New York Daily News\] After nine months of undergoing alternative medicine treatments for his disease, Jobs decided to allow for the use of conventional medicine in July 2004 due to the size of his tumor increasing. Jobs practiced Buddhism and was reportedly skeptical about mainstream medicine, instead stubbornly believing in unconventional methods to cure his ailments. Still, Dr. Jeffrey A. Norton, chief of surgical oncology at Stanford University, stated, “surgery is the only treatment modality that can result in a cure.” Norton was the one who removed Jobs’ tumor but alternative forms of treatment, such as a specialized diet and different meditation exercises, could have ultimately cost Jobs his life. Buddhist theories of medicine point to “three poisons” that cause people to get sick: greed, anger, and ignorance. Yet, why would a man who is so technologically-savvy as Steve Jobs be basing such important health decisions on ancient philosophies and natural remedies, especially when there have recently been more breakthroughs in cancer research than at any other point in history? [Did "Alternative Medicine" Kill Steve Jobs?](http://www.celebritydiagnosis.com/2011/10/did-alternative-medicine-kill-steve-jobs/) \[CelebrityDiagnosis.com\] In terms of his alternative medicine treatments, it is still not known what exactly Jobs did to treat his cancer. He did reportedly restrict his diet to only fruits or fruits and vegetables, consulted psychics, and tried a procedure known as hydrotherapy. Surgical removal of the tumor for patients whose disease is detected while it is still confined to the pancreas, have a five-year survival rate of 87 percent. Thus, the majority of patients live for quite a while. It is impossible to know whether surgery would have cured Jobs of his disease but his alternative medicine techniques, like acupuncture, were “not enough to change the course of the disease,” says Dr. Lowell Kobrin, a medical doctor who now focuses on acupuncture and herbal medicine at Northbend Medical Center in Coos Bay, Oregon. Kobrin added that the therapy could not affect cancer itself. Tim Birdsall, vice president of integrative medicine at the Cancer Treatment Centers of America, stated, “Once a cancer is established, in the vast majority of cases, simply changing the environment will not be sufficient to eradicate that established tumor.” While alternative medicine seems to be a beneficial compliment to conventional medicine, it cannot replace conventional medicine when trying to cure a dangerous disease. [Did Alternative Medicine Extend or Abbreviate Steve Jobs' Life?](http://www.scientificamerican.com/article.cfm?id=alternative-medicine-extend-abbreviate-steve-jobs-life&page=3) \[Scientific American\] Due to Jobs’ form of pancreatic cancer being less lethal that the most common form of pancreatic cancer known as adenocarcinoma, many experts believe that his decision to wait before opting for surgery was not necessarily a bad idea. Julie Fleshman, president and chief executive officer of the Pancreatic Cancer Action Network, said that patients in Jobs’ situation don’t automatically have to rush treatment. “The length of time before you have to make a decision about your treatment is not as quick as someone whose been diagnosed with an adenocarcinoma,” she added. Dr. Maged Rizk, a gastroenterologist at Cleveland Clinic, believed that Jobs waiting nine months for surgery was a bad decision. She said, “if it is an islet-cell tumor and the cells are \[typical of early cancer\], and as long as you don’t have symptoms, you can sit on it a bit.” Still, both Fleshman and Rizk agreed that alternative medicine treatments should not have been the sole methods of treatment for his disease. [Did Alternative Medicine Kill Steve Jobs?](http://www.livescience.com/16551-steve-jobs-alternative-medicine-pancreatic-cancer-treatment.html) \[LiveScience.com\] With the general consensus of medical experts being against the singular use of alternative medicine without conventional treatment, Steve Jobs agreed with them toward the end. Walter Isaacson, whose much-anticipated authorized biography on Jobs’ life is was released earlier this month, said that, before he died, the 56-year old Jobs had come to realize the mistake he made regarding his treatment. Isaacson said Jobs “wanted to talk about it, how he regretted it. I think he felt he should have been operated on \[it\] sooner.” Jobs was pushed to embrace conventional medicine by many confidants, including his sister, Mona Simpson, and Art Levinson, an Apple board member. In the end, Jobs realized the mistake he made and regretted the decision he made to fight the disease that plagued him for so many years. [Steve Jobs 'Regretted Trying to Beat Cancer with Alternative Medicine for So Long'](http://www.telegraph.co.uk/technology/apple/8841347/Steve-Jobs-regretted-trying-to-beat-cancer-with-alternative-medicine-for-so-long.html) \[The Telegraph\] ### Newsletter Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today. [Subscribe Now\!](https://www.hcplive.com/subscribe) Advertisement *** ## Related Content Advertisement [![Clinicians Encounter Patient Use of AI for Mental Health, With Darlene King, MD](https://cdn.sanity.io/images/0vv8moc6/hcplive/df61ec121213f81480f734b84f7d74d23faaee8e-1200x628.png?w=350&fit=crop&auto=format)](https://www.hcplive.com/view/clinicians-encounter-patient-use-ai-mental-health-darlene-king-md) [Clinicians Encounter Patient Use of AI for Mental Health, With Darlene King, MD](https://www.hcplive.com/view/clinicians-encounter-patient-use-ai-mental-health-darlene-king-md) By[Darlene King, MD](https://www.hcplive.com/authors/darlene-king-md) April 14th 2026 [![Alexander Blood, MD \\| Image Credit: American Heart Association](https://cdn.sanity.io/images/0vv8moc6/hcplive/54fb6a62d78a54faf41e4db054129a4d4474da69-1200x628.png?w=350&fit=crop&auto=format)](https://www.hcplive.com/view/ai-model-outperforms-clinicians-in-hcm-registry-data-extraction-with-alexander-blood-md) [AI Model Outperforms Clinicians in HCM Registry Data Extraction, With Alexander Blood, MD](https://www.hcplive.com/view/ai-model-outperforms-clinicians-in-hcm-registry-data-extraction-with-alexander-blood-md) By[Alexander Blood, MD](https://www.hcplive.com/authors/alexander-blood-md) April 14th 2026 [![Rebuilding Trust, Increasing Living Donor Transplant In Black Kidney Candidates, With Pranav Garimella, MBBS, MPH](https://cdn.sanity.io/images/0vv8moc6/hcplive/17079c2da7bfddb0f6cb2f5b8ebaf40ba27017a4-1200x628.png?w=350&fit=crop&auto=format)](https://www.hcplive.com/view/rebuilding-trust-increasing-living-donor-transplant-black-kidney-candidates-pranav-garimella) [Rebuilding Trust, Increasing Living Donor Transplant In Black Kidney Candidates, With Pranav Garimella, MBBS, MPH](https://www.hcplive.com/view/rebuilding-trust-increasing-living-donor-transplant-black-kidney-candidates-pranav-garimella) By[Pranav Garimella, MBBS, MPH](https://www.hcplive.com/authors/pranav-garimella-mbbs-mph) April 14th 2026 [![Brensocatib Phase 2b Study in HS Does Not Meet Endpoints, Program Discontinued](https://cdn.sanity.io/images/0vv8moc6/hcplive/d8048845deac2eba53b8f3a6afcc75a830fb4036-1200x630.png?w=350&fit=crop&auto=format)](https://www.hcplive.com/view/brensocatib-phase-2b-study-hs-does-not-meet-endpoints-program-discontinued) [Brensocatib Phase 2b Study in HS Does Not Meet Endpoints, Program Discontinued](https://www.hcplive.com/view/brensocatib-phase-2b-study-hs-does-not-meet-endpoints-program-discontinued) By[Tim Smith](https://www.hcplive.com/authors/tim-smith) April 14th 2026 [![Short Sleep Tied to Next-Day Depression in Suicidal Youth, With Delainey Wescott, PhD](https://cdn.sanity.io/images/0vv8moc6/hcplive/0c6a5d3b4e4635a39ca44d92ef7d00dd54cbcb4c-1200x628.png?w=350&fit=crop&auto=format)](https://www.hcplive.com/view/short-sleep-tied-next-day-depression-suicidal-youth-delainey-wescott-phd) [Short Sleep Tied to Next-Day Depression in Suicidal Youth, With Delainey Wescott, PhD](https://www.hcplive.com/view/short-sleep-tied-next-day-depression-suicidal-youth-delainey-wescott-phd) By[Delainey Wescott, PhD](https://www.hcplive.com/authors/delainey-wescott-phd) April 14th 2026 ## Latest CME [![20th Annual Controversies in Modern Eye Care](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/l01hgc5xkksh-CIME26TICatalog750x361.png) In-Person Event20th Annual Controversies in Modern Eye Care April 19, 2026](https://www.gotoper.com/courses/cime?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [Register now\!](https://www.gotoper.com/courses/cime?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/4p61lbi98jvq-TICatalog750x3612x631.png) Video(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments Yasha Modi, MD; Carolyn Majcher, OD, FAAO, FORS](https://www.gotoper.com/courses/clinical-consultations-framing-a-new-approach-to-geographic-atrophy-management-expert-insights-into-recent-developments?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/clinical-consultations-framing-a-new-approach-to-geographic-atrophy-management-expert-insights-into-recent-developments?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/4p61lbi98jvq-TICatalog750x3612x631.png) Video(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments Yasha Modi, MD; Carolyn Majcher, OD, FAAO, FORS](https://www.gotoper.com/courses/clinical-consultations-framing-a-new-approach-to-geographic-atrophy-management-expert-insights-into-recent-developments?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/clinical-consultations-framing-a-new-approach-to-geographic-atrophy-management-expert-insights-into-recent-developments?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Addressing Unmet Needs in HER2+ Metastatic BTC](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/rz7ssigwynji-PER_PodSeries_BTC_Pod1_TICatalog750x3612x.png) VideoAddressing Unmet Needs in HER2+ Metastatic BTC Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA](https://www.gotoper.com/courses/addressing-unmet-needs-in-her2-metastatic-btc?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/addressing-unmet-needs-in-her2-metastatic-btc?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/lan4sozx8lsu-Roswell25TICatalog750x361.png) In-Person + Virtual EventUpstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting April 25-26, 2026](https://www.gotoper.com/courses/upstate-new-york-hematology-hematologic-oncology-conference-a-review-of-the-67th-ash-annual-meeting?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/upstate-new-york-hematology-hematologic-oncology-conference-a-review-of-the-67th-ash-annual-meeting?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/1r1apfwoh975-ADCCDKArchiveBanners_TIDetail800x450.jpg) VideoCase-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD](https://www.gotoper.com/courses/case-by-case-application-of-hif-phis-for-the-treatment-of-anemia-in-patients-with-ckd-f7al?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/case-by-case-application-of-hif-phis-for-the-treatment-of-anemia-in-patients-with-ckd-f7al?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/1r1apfwoh975-ADCCDKArchiveBanners_TIDetail800x450.jpg) VideoCase-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD](https://www.gotoper.com/courses/case-by-case-application-of-hif-phis-for-the-treatment-of-anemia-in-patients-with-ckd-f7al?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/case-by-case-application-of-hif-phis-for-the-treatment-of-anemia-in-patients-with-ckd-f7al?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/lxw9mjsz4juq-HTRS25_Hepatic_myCMEBanners_MyCME800x385.png) VideoThe Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria Sammy Saab, MD, MPH, AGAF, FACG, FAASLD; Vandana Khungar, MD, MSc; Christopher V. Almario, MD, MSHPM](https://www.gotoper.com/courses/the-role-of-the-multidisciplinary-care-team-in-the-diagnosis-and-management-of-acute-hepatic-porphyria-hc4e?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/the-role-of-the-multidisciplinary-care-team-in-the-diagnosis-and-management-of-acute-hepatic-porphyria-hc4e?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/lxw9mjsz4juq-HTRS25_Hepatic_myCMEBanners_MyCME800x385.png) VideoThe Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria Sammy Saab, MD, MPH, AGAF, FACG, FAASLD; Vandana Khungar, MD, MSc; Christopher V. Almario, MD, MSHPM](https://www.gotoper.com/courses/the-role-of-the-multidisciplinary-care-team-in-the-diagnosis-and-management-of-acute-hepatic-porphyria-hc4e?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/the-role-of-the-multidisciplinary-care-team-in-the-diagnosis-and-management-of-acute-hepatic-porphyria-hc4e?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/10izyuwnvl47-RRRetina_nAMD-DMEWinter25_TICatalog750x361.png) Video(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME David M. Brown, MD, FACS; Dilraj S. Grewal, MD](https://www.gotoper.com/courses/rapid-reviews-in-retina-emerging-updates-from-winter-2025-addressing-the-wealth-of-new-data-in-treatments-for-namd-and-dme?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/rapid-reviews-in-retina-emerging-updates-from-winter-2025-addressing-the-wealth-of-new-data-in-treatments-for-namd-and-dme?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/10izyuwnvl47-RRRetina_nAMD-DMEWinter25_TICatalog750x361.png) Video(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME David M. Brown, MD, FACS; Dilraj S. Grewal, MD](https://www.gotoper.com/courses/rapid-reviews-in-retina-emerging-updates-from-winter-2025-addressing-the-wealth-of-new-data-in-treatments-for-namd-and-dme?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/rapid-reviews-in-retina-emerging-updates-from-winter-2025-addressing-the-wealth-of-new-data-in-treatments-for-namd-and-dme?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![ Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/ri5iomf2n5nz-ASRS_XLRP_TICatalog750x3611.png) VideoLiving With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience Lejla Vajzovic, MD, FASRS; Ramiro Maldonado, MD](https://www.gotoper.com/courses/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![ Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/ri5iomf2n5nz-ASRS_XLRP_TICatalog750x3611.png) VideoLiving With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience Lejla Vajzovic, MD, FASRS; Ramiro Maldonado, MD](https://www.gotoper.com/courses/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/72fzug9uvzzu-MBCC25_ISS_PMCPC_WebBanners_TICatalog750x361.png) MultimediaCommunity Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC](https://www.gotoper.com/courses/community-practice-connections-optimizing-treatment-outcomes-and-preserving-fertility-in-premenopausal-hr-breast-cancer?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/community-practice-connections-optimizing-treatment-outcomes-and-preserving-fertility-in-premenopausal-hr-breast-cancer?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/igbn7kc13r9g-CCC25_nAMDDME_TICatalog750x3612x.png) Video(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation Veeral Sheth, MD, MBA, FASRS, FACS; Mark R. Barakat, MD, FASRS; Geeta Lalwani, MD; Xiao Yi Zhou, MD](https://www.gotoper.com/courses/collaborative-community-connections-mastering-the-management-of-namd-and-dme-through-therapeutic-innovation?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/collaborative-community-connections-mastering-the-management-of-namd-and-dme-through-therapeutic-innovation?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![ Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/ri5iomf2n5nz-ASRS_XLRP_TICatalog750x3611.png) VideoLiving With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience Lejla Vajzovic, MD, FASRS; Ramiro Maldonado, MD](https://www.gotoper.com/courses/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![ Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/ri5iomf2n5nz-ASRS_XLRP_TICatalog750x3611.png) VideoLiving With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience Lejla Vajzovic, MD, FASRS; Ramiro Maldonado, MD](https://www.gotoper.com/courses/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/patient-provider-and-caregiver-connection-living-with-x-linked-retinitis-pigmentosa-what-we-can-learn-from-a-patients-experience?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/igbn7kc13r9g-CCC25_nAMDDME_TICatalog750x3612x.png) Video(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation Veeral Sheth, MD, MBA, FASRS, FACS; Mark R. Barakat, MD, FASRS; Geeta Lalwani, MD; Xiao Yi Zhou, MD](https://www.gotoper.com/courses/collaborative-community-connections-mastering-the-management-of-namd-and-dme-through-therapeutic-innovation?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/collaborative-community-connections-mastering-the-management-of-namd-and-dme-through-therapeutic-innovation?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/8q4nbzp3xvdd-PERPodcastSeries_BTC_Pod2_TICatalog750x3612x.png) VideoFrom Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS](https://www.gotoper.com/courses/from-bench-to-bedside-paradigm-shifts-in-her2-metastatic-btc-treatment?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/from-bench-to-bedside-paradigm-shifts-in-her2-metastatic-btc-treatment?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Collaborative Care Symposium](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/sfdryshzuc1v-TICatalog750x3612x342.png) Virtual EventCollaborative Care Symposium May 2-3, 2026](https://www.gotoper.com/courses/collaborative-care-symposium?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/collaborative-care-symposium?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Proactive Adverse Event Management for HER2+ BTC Treatments](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/gcrqdi7eprzi-PER_PodSeries_BTC_Pod3_TICatalog750x3612x.png) VideoProactive Adverse Event Management for HER2+ BTC Treatments Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO](https://www.gotoper.com/courses/proactive-adverse-event-management-for-her2-btc-treatments?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/proactive-adverse-event-management-for-her2-btc-treatments?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/ndfh02xn9dzr-CRU25_ISS_Glaucoma_myCMEBanners_MyCME800x385.png) VideoNavigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge Deborah Ristvedt, DO; Melissa Tawa, OD, FAAO](https://www.gotoper.com/courses/navigating-the-glaucoma-therapeutic-and-surgical-landscape-from-conventional-to-cutting-edge?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/navigating-the-glaucoma-therapeutic-and-surgical-landscape-from-conventional-to-cutting-edge?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/m0tuj7iifza3-ONS25_Ovarian_TICatalog750x3612x1.png) VideoShow Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer Ritu Salani, MD, MBA; Jill Alldredge, MD; Emely Alfaro, MS, RN, CNS, OCN](https://www.gotoper.com/courses/show-me-your-care-plan-insights-for-oncology-nurses-integrating-recent-developments-to-improve-outcomes-for-patients-with-platinum-resistant-ovarian-cancer-elfw?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/show-me-your-care-plan-insights-for-oncology-nurses-integrating-recent-developments-to-improve-outcomes-for-patients-with-platinum-resistant-ovarian-cancer-elfw?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/sdlxwtp44t32-CRU25_ISS_NK_myCMEBanners_MyCME800x385.png) Video(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes Melissa Barnett, OD, FAAO, FSLS, FBCLA; Cecelia Koetting, OD, FAAO, DipABO; Quan Đông Nguyễn, MD, MSc; Jennifer Li, MD](https://www.gotoper.com/courses/neurotrophic-keratitis-multidisciplinary-approaches-to-enhance-patient-outcomes?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/neurotrophic-keratitis-multidisciplinary-approaches-to-enhance-patient-outcomes?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/sdlxwtp44t32-CRU25_ISS_NK_myCMEBanners_MyCME800x385.png) Video(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes Melissa Barnett, OD, FAAO, FSLS, FBCLA; Cecelia Koetting, OD, FAAO, DipABO; Quan Đông Nguyễn, MD, MSc; Jennifer Li, MD](https://www.gotoper.com/courses/neurotrophic-keratitis-multidisciplinary-approaches-to-enhance-patient-outcomes?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/neurotrophic-keratitis-multidisciplinary-approaches-to-enhance-patient-outcomes?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/qcag6duoxbzo-ACP25_CGM_TICatalog750x3612x1.png) VideoCases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD](https://www.gotoper.com/courses/cases-and-conversations-a-horizon-view-of-continuous-monitoring-systems-for-diabetes-management-n3wp?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/cases-and-conversations-a-horizon-view-of-continuous-monitoring-systems-for-diabetes-management-n3wp?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Expert Illustrations and Commentaries™: Managing Hyperphosphatemia in CKD—A Closer Look at the Paracellular Pathway](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/y4ert3rtufci-ANNA25_CKD_TICatalog750x3612x1.png) VideoExpert Illustrations and Commentaries™: Managing Hyperphosphatemia in CKD—A Closer Look at the Paracellular Pathway Anil K. Agarwal, MD; Nissreen Elfadawy, MD, MS, FASN, FAST](https://www.gotoper.com/courses/expert-illustrations-and-commentaries-managing-hyperphosphatemia-in-ckda-closer-look-at-the-paracellular-pathway?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/expert-illustrations-and-commentaries-managing-hyperphosphatemia-in-ckda-closer-look-at-the-paracellular-pathway?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/ymqok2s4swdg-ASCRS25_TICatalog750x3612x2.png) Video(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management Marjan Farid, MD; John Hovanesian, MD; Beeran Meghpara, MD](https://www.gotoper.com/courses/the-neural-network-exploring-the-role-of-neuromodulation-in-dry-eye-disease-management-6q0a?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/the-neural-network-exploring-the-role-of-neuromodulation-in-dry-eye-disease-management-6q0a?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/ymqok2s4swdg-ASCRS25_TICatalog750x3612x2.png) Video(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management Marjan Farid, MD; John Hovanesian, MD; Beeran Meghpara, MD](https://www.gotoper.com/courses/the-neural-network-exploring-the-role-of-neuromodulation-in-dry-eye-disease-management-6q0a?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/the-neural-network-exploring-the-role-of-neuromodulation-in-dry-eye-disease-management-6q0a?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/rfr4hzmsgoxs-ASCRS25_IOLs_WebBanners_TICatalog750x361.png) Video(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success Tanner Ferguson, MD; Taj Nasser, MD, FWCRS](https://www.gotoper.com/courses/toric-iols-unleashed-from-technological-progress-to-patient-success?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/toric-iols-unleashed-from-technological-progress-to-patient-success?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/c1asofgfjc4q-MRLDMETICatalog750x361.png) Video(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR David A. Eichenbaum, MD](https://www.gotoper.com/courses/clinical-case-connections-understanding-the-impact-of-advances-in-treatment-for-dme-and-dr?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/clinical-case-connections-understanding-the-impact-of-advances-in-treatment-for-dme-and-dr?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/c1asofgfjc4q-MRLDMETICatalog750x361.png) Video(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR David A. Eichenbaum, MD](https://www.gotoper.com/courses/clinical-case-connections-understanding-the-impact-of-advances-in-treatment-for-dme-and-dr?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/clinical-case-connections-understanding-the-impact-of-advances-in-treatment-for-dme-and-dr?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/qqt1jbn4kcnm-MRLnAMDTICatalog750x361.png) Video(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD Nathan C. Steinle, MD](https://www.gotoper.com/courses/clinical-case-connections-expert-insights-on-applying-therapeutic-innovations-in-namd?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/clinical-case-connections-expert-insights-on-applying-therapeutic-innovations-in-namd?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/h0e1xgmkslph-TICatalog750x3612x87.png) AudioShow Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer Ritu Salani, MD, MBA; Emely Alfaro, MS, RN, CNS, OCN; Jill Alldredge, MD](https://www.gotoper.com/courses/show-me-your-care-plan-insights-for-oncology-nurses-integrating-recent-developments-to-improve-outcomes-for-patients-with-platinum-resistant-ovarian-cancer-0bs0?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/show-me-your-care-plan-insights-for-oncology-nurses-integrating-recent-developments-to-improve-outcomes-for-patients-with-platinum-resistant-ovarian-cancer-0bs0?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Cases and Conversations™: Improving Identification and Management of Patients with Congenital Adrenal Hyperplasia (CAH)](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/b75so9magft1-TICatalog750x3612x601.png) VideoCases and Conversations™: Improving Identification and Management of Patients with Congenital Adrenal Hyperplasia (CAH) Perrin C White, MD; Richard J. Auchus, MD, PhD; Mimi Kim, MD, MSc](https://www.gotoper.com/courses/cases-and-conversations-improving-identification-and-management-of-patients-with-congenital-adrenal-hyperplasia-cah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/cases-and-conversations-improving-identification-and-management-of-patients-with-congenital-adrenal-hyperplasia-cah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Cases and Conversations™: Improving Identification and Management of Patients with Congenital Adrenal Hyperplasia (CAH)](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/b75so9magft1-TICatalog750x3612x601.png) VideoCases and Conversations™: Improving Identification and Management of Patients with Congenital Adrenal Hyperplasia (CAH) Perrin C White, MD; Richard J. Auchus, MD, PhD; Mimi Kim, MD, MSc](https://www.gotoper.com/courses/cases-and-conversations-improving-identification-and-management-of-patients-with-congenital-adrenal-hyperplasia-cah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/cases-and-conversations-improving-identification-and-management-of-patients-with-congenital-adrenal-hyperplasia-cah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/qqt1jbn4kcnm-MRLnAMDTICatalog750x361.png) Video(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD Nathan C. Steinle, MD](https://www.gotoper.com/courses/clinical-case-connections-expert-insights-on-applying-therapeutic-innovations-in-namd?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/clinical-case-connections-expert-insights-on-applying-therapeutic-innovations-in-namd?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/rfr4hzmsgoxs-ASCRS25_IOLs_WebBanners_TICatalog750x361.png) Video(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success Tanner Ferguson, MD; Taj Nasser, MD, FWCRS](https://www.gotoper.com/courses/toric-iols-unleashed-from-technological-progress-to-patient-success?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/toric-iols-unleashed-from-technological-progress-to-patient-success?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/c667g7ip86ev-PERPodcastSeries_ALS_Pod1_WebBanners_TICatalog750x361.png) AudioPER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS) Richard Bedlack, MD, PhD](https://www.gotoper.com/courses/per-podcast-maximizing-the-multidisciplinary-care-outcomes-of-patients-with-amyotrophic-lateral-sclerosis-als?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/per-podcast-maximizing-the-multidisciplinary-care-outcomes-of-patients-with-amyotrophic-lateral-sclerosis-als?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/lfoy632hm4k3-PERPodcastSeries_ALS_Pod2_WebBanners_TICatalog750x361.png) AudioPER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS) Terry Heiman-Patterson, MD](https://www.gotoper.com/courses/per-podcast-best-strategies-for-approaching-the-diagnosis-of-amyotrophic-lateral-sclerosis-als?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/per-podcast-best-strategies-for-approaching-the-diagnosis-of-amyotrophic-lateral-sclerosis-als?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Expert Illustrations & Commentaries™: Visualizing the Role of the Complement Pathway in Paroxysmal Nocturnal Hemoglobinuria](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/zn7wbzsfllei-TICatalog750x3612x33.png) MultimediaExpert Illustrations & Commentaries™: Visualizing the Role of the Complement Pathway in Paroxysmal Nocturnal Hemoglobinuria Caroline Piatek, MD; Ilene Weitz, MD](https://www.gotoper.com/courses/expert-illustrations-commentaries-visualizing-the-role-of-the-complement-pathway-in-paroxysmal-nocturnal-hemoglobinuria?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/expert-illustrations-commentaries-visualizing-the-role-of-the-complement-pathway-in-paroxysmal-nocturnal-hemoglobinuria?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/bfifjatwf6ua-TICatalog750x3612x11.png) Video(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD](https://www.gotoper.com/courses/2025-cime-navigating-pharmacological-presbyopia-treatment-for-enhanced-patient-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/2025-cime-navigating-pharmacological-presbyopia-treatment-for-enhanced-patient-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/x9vh23n5lon9-TICatalog750x3612x641.png) VideoAddressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women Danielle Nance, MD; Kimberley Youkhana, MD](https://www.gotoper.com/courses/addressing-healthcare-inequities-detecting-and-managing-the-uncommon-hemophilia-in-women?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/addressing-healthcare-inequities-detecting-and-managing-the-uncommon-hemophilia-in-women?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/x9vh23n5lon9-TICatalog750x3612x641.png) VideoAddressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women Danielle Nance, MD; Kimberley Youkhana, MD](https://www.gotoper.com/courses/addressing-healthcare-inequities-detecting-and-managing-the-uncommon-hemophilia-in-women?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/addressing-healthcare-inequities-detecting-and-managing-the-uncommon-hemophilia-in-women?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/pnkrnaz3vky4-RADTSWTICatalog750x361.png) VideoUnderstanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD) Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD](https://www.gotoper.com/courses/understanding-topical-steroid-withdrawal-tsw-in-patients-with-atopic-dermatitis-ad-c78o?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/understanding-topical-steroid-withdrawal-tsw-in-patients-with-atopic-dermatitis-ad-c78o?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/bfifjatwf6ua-TICatalog750x3612x11.png) Video(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD](https://www.gotoper.com/courses/2025-cime-navigating-pharmacological-presbyopia-treatment-for-enhanced-patient-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/2025-cime-navigating-pharmacological-presbyopia-treatment-for-enhanced-patient-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/nq6bshrgre1r-TICatalog750x3612x701.png) VideoPER Postgame™: Updates from ANNA in the Management of IgA Nephropathy Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA](https://www.gotoper.com/courses/per-postgame-updates-in-the-management-of-iga-nephropathy?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/per-postgame-updates-in-the-management-of-iga-nephropathy?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/6mnsbnihwq2t-TICatalog750x3612x214.png) VideoNeurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; John Hovanesian, MD, FACS](https://www.gotoper.com/courses/neurotrophic-keratitis-insights-an-interactive-corneal-sensitivity-testing-workshop?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/neurotrophic-keratitis-insights-an-interactive-corneal-sensitivity-testing-workshop?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![SimulatEd™ in Hypercortisolism and Type 2 Diabetes: Identifying Patients with Hypercortisolism](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/6ybpjsyms0fo-TICatalog750x3612x2911.png) Case-based SimulationSimulatEd™ in Hypercortisolism and Type 2 Diabetes: Identifying Patients with Hypercortisolism Richard E. Pratley, MD; Matthew P. Gilbert, DO, MPH](https://www.gotoper.com/courses/simulated-in-hypercortisolism-and-type-2-diabetes-identifying-patients-with-hypercortisolism?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/simulated-in-hypercortisolism-and-type-2-diabetes-identifying-patients-with-hypercortisolism?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/h3ryntwhq63o-CIMEDemotexTICatalog750x3612x1.png) Video(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD](https://www.gotoper.com/courses/small-mites-big-impact-revolutionizing-demodex-blepharitis-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/small-mites-big-impact-revolutionizing-demodex-blepharitis-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/16d7ydt8wpt6-TICatalog750x3612x2321.png) VideoClinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc](https://www.gotoper.com/courses/clinical-consultations-providing-holistic-care-for-complex-cases-of-psoriasis-with-cardiovascular-comorbidities?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/clinical-consultations-providing-holistic-care-for-complex-cases-of-psoriasis-with-cardiovascular-comorbidities?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/16d7ydt8wpt6-TICatalog750x3612x2321.png) VideoClinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc](https://www.gotoper.com/courses/clinical-consultations-providing-holistic-care-for-complex-cases-of-psoriasis-with-cardiovascular-comorbidities?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/clinical-consultations-providing-holistic-care-for-complex-cases-of-psoriasis-with-cardiovascular-comorbidities?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care](https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/h3ryntwhq63o-CIMEDemotexTICatalog750x3612x1.png) Video(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD](https://www.gotoper.com/courses/small-mites-big-impact-revolutionizing-demodex-blepharitis-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/small-mites-big-impact-revolutionizing-demodex-blepharitis-care?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/7wvhdmjbpzq3-ASCORRMMTICatalog750x3611.png) VideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD](https://www.gotoper.com/courses/cases-and-conversations-sorting-through-the-expanding-treatment-options-for-patients-with-relapsedrefractory-multiple-myeloma-wink?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/cases-and-conversations-sorting-through-the-expanding-treatment-options-for-patients-with-relapsedrefractory-multiple-myeloma-wink?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/yghd89xssfic-ASCO25_ADCMBCTICatalog750x3611.png) VideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS](https://www.gotoper.com/courses/cases-conversations-transforming-aml-careprecision-strategies-evolving-therapies-and-clinical-insights-91pp?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/cases-conversations-transforming-aml-careprecision-strategies-evolving-therapies-and-clinical-insights-91pp?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/2bg381rlbfzn-ASCO25_MFPVTICatalog750x361.png) VideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD](https://www.gotoper.com/courses/medical-crossfire-improving-patient-outcomes-in-myeloproliferative-neoplasms-with-novel-therapeutic-approaches-1?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/medical-crossfire-improving-patient-outcomes-in-myeloproliferative-neoplasms-with-novel-therapeutic-approaches-1?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 1)](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/c1bwjcrftf7t-BurstCMEV3_CKDTITICatalog750x3611.png) MultimediaBurst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 1) Suneel Udani, MD](https://www.gotoper.com/courses/burst-cme-managing-fluid-overload-in-patients-with-chronic-kidney-disease?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/burst-cme-managing-fluid-overload-in-patients-with-chronic-kidney-disease?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![ Looking Beneath the Surface: Latest Updates in Identifying and Managing Hypercortisolism in Patients with Type 2 Diabetes](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/4xtdfqm5y16h-TICatalog750x3612x9.png) VideoLooking Beneath the Surface: Latest Updates in Identifying and Managing Hypercortisolism in Patients with Type 2 Diabetes Richard E. Pratley, MD; Vivian Fonseca, MD, FRCP](https://www.gotoper.com/courses/per-postgame-looking-beneath-the-surface-latest-updates-in-identifying-and-managing-hypercortisolism-in-patients-with-type-2-diabetes?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/per-postgame-looking-beneath-the-surface-latest-updates-in-identifying-and-managing-hypercortisolism-in-patients-with-type-2-diabetes?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/gd8dvx0r87tz-TICatalog750x3612x61.png) VideoNavigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management Andrew Alexis, MD, MPH; Leon Kircik, MD](https://www.gotoper.com/courses/navigating-safety-data-with-janus-kinase-jak-inhibitors-in-atopic-dermatitis-ad-management-et4u?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/navigating-safety-data-with-janus-kinase-jak-inhibitors-in-atopic-dermatitis-ad-management-et4u?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/0vkef67cs6nz-TICatalog750x3612x11.png) VideoRapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease SriniVas Sadda, MD, FARVO; Nathan Steinle, MD](https://www.gotoper.com/courses/rapid-reviews-in-retina-emerging-updates-from-spring-2025addressing-the-wealth-of-new-data-in-treatments-for-neovascular-retinal-disease?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/rapid-reviews-in-retina-emerging-updates-from-spring-2025addressing-the-wealth-of-new-data-in-treatments-for-neovascular-retinal-disease?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Interventional Dry Eye: A Stepwise Treatment & Management Approach](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/37zzqxcjm42r-AOADEDTICatalog750x3611.png) VideoInterventional Dry Eye: A Stepwise Treatment & Management Approach Mark Schaeffer, OD, FAAO; Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO, FAAOMS; Selina R. McGee, OD, FAAO](https://www.gotoper.com/courses/interventional-dry-eye-a-stepwise-treatment-and-management-approach?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/interventional-dry-eye-a-stepwise-treatment-and-management-approach?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/eqalj1ca37qk-TICatalog750x3612x51.png) VideoAssessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD](https://www.gotoper.com/courses/assessing-the-evidence-for-ox40-ox40l-axis-inhibition-for-the-treatment-of-atopic-dermatitis-eaxm?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/assessing-the-evidence-for-ox40-ox40l-axis-inhibition-for-the-treatment-of-atopic-dermatitis-eaxm?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 2)](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/c1bwjcrftf7t-BurstCMEV3_CKDTITICatalog750x3611.png) MultimediaBurst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 2) Suneel Udani, MD](https://www.gotoper.com/courses/burst-cme-managing-fluid-overload-in-patients-with-chronic-kidney-disease-part-2?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/burst-cme-managing-fluid-overload-in-patients-with-chronic-kidney-disease-part-2?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/ox6vub9txysu-TICatalog750x3612x71.png) VideoPatient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD](https://www.gotoper.com/courses/patient-provider-and-caregiver-connection-turning-a-new-leaf-in-acute-pain-management-how-recent-advancements-impact-the-treatment-paradigm?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/patient-provider-and-caregiver-connection-turning-a-new-leaf-in-acute-pain-management-how-recent-advancements-impact-the-treatment-paradigm?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/njdnnzcxsiim-ASRS_XLRP_WebBannersNEWTitle_ASRS_XLRP_TICatalog750x361.png) Video(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS](https://www.gotoper.com/courses/collaborating-across-the-continuum-best-practices-in-patient-centric-team-management-of-xlrp-0vbw?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/collaborating-across-the-continuum-best-practices-in-patient-centric-team-management-of-xlrp-0vbw?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/l0szys11gab0-eec7259e-fdaf-4450-8aa4-843267866004.jpg) MultimediaBurst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice Jerry Bagel, MD, MS](https://www.gotoper.com/courses/burst-cme-optimizing-care-for-patients-with-psoriasis-incorporating-a-buy-and-bill-model-for-biologic-agents-into-dermatological-practice?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/burst-cme-optimizing-care-for-patients-with-psoriasis-incorporating-a-buy-and-bill-model-for-biologic-agents-into-dermatological-practice?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/ouwd4qnjzqwf-ASRS_MacTel_TICatalog750x361.png) Video(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS](https://www.gotoper.com/courses/the-evolution-of-mactel-management-integrating-neuroprotective-therapies-into-clinical-practice-62lr?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/the-evolution-of-mactel-management-integrating-neuroprotective-therapies-into-clinical-practice-62lr?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![ Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/qsk84tt8r2ij-SOCALMDDTICatalog750x361.png) VideoLive Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C](https://www.gotoper.com/courses/2025-socal-psych-expert-illustrations-commentary-visualizing-novel-therapeutic-targets-for-patients-with-major-depressive-disorder?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/2025-socal-psych-expert-illustrations-commentary-visualizing-novel-therapeutic-targets-for-patients-with-major-depressive-disorder?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/ldpdqdf40tvd-RRR25_Summer_NRD_TICatalog750x3612x1.png) Video(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS](https://www.gotoper.com/courses/rapid-reviews-in-retina-emerging-updates-from-summer-2025addressing-the-wealth-of-new-data-in-treatments-for-neovascular-retinal-disease?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/rapid-reviews-in-retina-emerging-updates-from-summer-2025addressing-the-wealth-of-new-data-in-treatments-for-neovascular-retinal-disease?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/enj0a03s0y5z-ASRS25_NEW_WebBanners_Updated_ASRS25_VEG_TICatalog750x361.png) Video(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD](https://www.gotoper.com/courses/a-forward-look-at-anti-vegf-therapies-a-paradigm-shift-in-neovascular-retinal-disease-management?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/a-forward-look-at-anti-vegf-therapies-a-paradigm-shift-in-neovascular-retinal-disease-management?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/4zhg5jz1vvvi-TICatalog750x3613.png) VideoCases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP](https://www.gotoper.com/courses/cases-and-conversations-biologic-matchmaking-in-psoriasis-finding-the-right-therapy-for-the-right-patient-7tcu?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/cases-and-conversations-biologic-matchmaking-in-psoriasis-finding-the-right-therapy-for-the-right-patient-7tcu?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/77r2aohwh5yi-TICatalog750x3612x58.png) VideoCollaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH Jean M. Elwing, MD, FCCP; Russel Hirsch, MD; John F. Morehous, MD](https://www.gotoper.com/courses/collaborating-across-the-continuum-the-pediatricians-vital-role-in-multidisciplinary-management-of-pediatric-pah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/collaborating-across-the-continuum-the-pediatricians-vital-role-in-multidisciplinary-management-of-pediatric-pah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/77r2aohwh5yi-TICatalog750x3612x58.png) VideoCollaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH Jean M. Elwing, MD, FCCP; Russel Hirsch, MD; John F. Morehous, MD](https://www.gotoper.com/courses/collaborating-across-the-continuum-the-pediatricians-vital-role-in-multidisciplinary-management-of-pediatric-pah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/collaborating-across-the-continuum-the-pediatricians-vital-role-in-multidisciplinary-management-of-pediatric-pah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/77r2aohwh5yi-TICatalog750x3612x58.png) VideoCollaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH Jean M. Elwing, MD, FCCP; Russel Hirsch, MD; John F. Morehous, MD](https://www.gotoper.com/courses/collaborating-across-the-continuum-the-pediatricians-vital-role-in-multidisciplinary-management-of-pediatric-pah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/collaborating-across-the-continuum-the-pediatricians-vital-role-in-multidisciplinary-management-of-pediatric-pah?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/yipisaym6igm-PPCC25_Vitiligo_WebBannersV2_PPCC25_Viti_TICatalog750x3611.png) VideoPatient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD](https://www.gotoper.com/courses/patient-provider-and-caregiver-connection-addressing-patient-challenges-with-holistic-approaches-to-vitiligo-management?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/patient-provider-and-caregiver-connection-addressing-patient-challenges-with-holistic-approaches-to-vitiligo-management?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/3ru5xlnlioem-CCC_Neovascular_TICatalog750x3611.png) Video(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD](https://www.gotoper.com/courses/community-collaborative-connections-optimizing-the-collaborative-care-of-neovascular-retinal-disease-in-a-new-age-of-treatment?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/community-collaborative-connections-optimizing-the-collaborative-care-of-neovascular-retinal-disease-in-a-new-age-of-treatment?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/mcyybmt7s0c5-SOCALSchizophreniaTICatalog750x361.png) Video(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia Gus Alva, MD, DFAPA; Ilan Melnick, MD](https://www.gotoper.com/courses/overcoming-barriers-to-long-acting-injectable-agents-in-schizophrenia?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/overcoming-barriers-to-long-acting-injectable-agents-in-schizophrenia?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/gbcbgzzruahm-CxC25_HeartFailure_TICatalog750x3612x.png) VideoCases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence Edgar V. Lerma, MD; Anuradha Lala-Trindade, MD](https://www.gotoper.com/courses/cases-and-conversations-mineralocorticoid-receptor-antagonists-in-patients-with-hfaugmenting-current-guidelines-with-emerging-evidence?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/cases-and-conversations-mineralocorticoid-receptor-antagonists-in-patients-with-hfaugmenting-current-guidelines-with-emerging-evidence?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/qwthl1m8frlz-SSM26_HS_TICatalog750x3612x1.png) VideoHidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches Hadar Lev-Tov, MD; Martina Porter, MD](https://www.gotoper.com/courses/hidradenitis-suppurativa-diving-deeper-into-disease-pathogenesis-severity-assessment-and-holistic-management-approaches?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/hidradenitis-suppurativa-diving-deeper-into-disease-pathogenesis-severity-assessment-and-holistic-management-approaches?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/sy1pxc8q7s1i-BurstCME25_Glucose_WebBanners_BurstCME25_TICatalog750x36111.png) VideoBurst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients Jennifer Green, MD; Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP](https://www.gotoper.com/courses/burst-cme-cgm-continuous-glucose-monitoring-considerations-maximizing-quality-of-life-for-patients?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/burst-cme-cgm-continuous-glucose-monitoring-considerations-maximizing-quality-of-life-for-patients?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [![ Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update](https://media.thoughtindustries.com/thoughtindustries/image/upload/v1/course-uploads/07c0d4e1-23aa-4e1a-8c5f-f2569da581c0/tp7povica5jm-CACHyperlipidemiaTICatalog750x361.png) VideoProgress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin](https://www.gotoper.com/courses/cases-and-conversations-progress-in-hyperlipidemia-management-to-reduce-ascvd-risk-an-illustrated-update?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) [View more](https://www.gotoper.com/courses/cases-and-conversations-progress-in-hyperlipidemia-management-to-reduce-ascvd-risk-an-illustrated-update?utm_source=hcplive&utm_medium=article&utm_campaign=cmeDeck) Previous slide Next slide Advertisement Advertisement ## Trending on HCPLive [1FDA Approves Sparsentan for Focal Segmental Glomerulosclerosis](https://www.hcplive.com/view/fda-approves-sparsentan-for-focal-segmental-glomerulosclerosis) [2Why Sparsentan’s FDA Approval Marks a Turning Point in FSGS, With Howard Tratchman, MD](https://www.hcplive.com/view/why-sparsentan-fda-approval-marks-a-turning-point-in-fsgs-with-howard-tratchman-md) [3Brensocatib Phase 2b Study in HS Does Not Meet Endpoints, Program Discontinued](https://www.hcplive.com/view/brensocatib-phase-2b-study-hs-does-not-meet-endpoints-program-discontinued) [4Socioeconomic Pressures and Clinical Gains in Heart Disease, With Suyog Mokashi, MD](https://www.hcplive.com/view/socioeconomic-pressures-and-clinical-gains-in-heart-disease-with-suyog-mokashi-md) [5The Early-Life Window: Can Food Allergy Be Prevented Before It Begins?](https://www.hcplive.com/view/early-life-window-can-food-allergy-prevented-before-begins-) - [About Us](https://www.hcplive.com/about) - [Advertise](https://www.hcplive.com/advertise) - [Editorial](https://www.hcplive.com/editorial) - [Contact Us](https://www.hcplive.com/contact-us) - [Do Not Sell My Information](https://www.mjhlifesciences.com/ccpa?domain=www.hcplive.com) - [Privacy](https://www.hcplive.com/privacy) - [Terms & Conditions](https://www.hcplive.com/terms) - Cookie settings Contact Info 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 - [![Contagion Live](https://www.hcplive.com/PartnerLogos/contagionLive_white.png)](https://www.contagionlive.com/) - [![CGT Live](https://www.hcplive.com/PartnerLogos/CGT_KO_NoTag.png)](https://www.cgtlive.com/) - [![Neurology Live](https://www.hcplive.com/PartnerLogos/Neuro_white.png)](https://www.neurologylive.com/) - [![HCP Live](https://www.hcplive.com/PartnerLogos/HCPlive_white.png)](https://www.hcplive.com/) - [![Oncology Live](https://www.hcplive.com/PartnerLogos/OncLive_white.png)](https://www.onclive.com/) - [![Contemporary Pediatrics](https://www.hcplive.com/PartnerLogos/contemporary_pediatrics_inverted_logo.png)](https://www.contemporarypediatrics.com/) - [![Contemporary OBGYN](https://www.hcplive.com/PartnerLogos/contemporaryobgyn_inverted_logo.png)](https://www.contemporaryobgyn.net/) - [![Urology Times](https://www.hcplive.com/PartnerLogos/ut_logo_white.png)](https://www.urologytimes.com/) - [![The Educated Patient](https://www.hcplive.com/PartnerLogos/EP_Logo.png)](https://www.theeducatedpatient.com/) - [![Patient Care Online](https://www.hcplive.com/PartnerLogos/PatientCare_white.png)](https://www.patientcareonline.com/) ![HCP Live Network](https://www.hcplive.com/PartnerLogos/hcplive_networkKO.png) ![Brand Logo](https://www.hcplive.com/an_mjhls_brand_ko.webp) © 2026 MJH Life Sciences® All rights reserved. [Home](https://www.hcplive.com/) [About Us](https://www.hcplive.com/about-us) [News](https://www.hcplive.com/news) [Contact Us](https://www.hcplive.com/contact-us)
Readable Markdown	Although alternative medicine is a good compliment to conventional medical treatment, Steve Jobs' sole reliance on alternative medicine treatment may be the primary factor for his untimely death. ![](https://cdn.sanity.io/images/0vv8moc6/hcplive/5f9cfbc7d54755c137d9c53fe0ce60044356bfb4-300x150.jpg?w=300&max-h=150&fit=crop&auto=format) ![](https://cdn.sanity.io/images/0vv8moc6/hcplive/5f9cfbc7d54755c137d9c53fe0ce60044356bfb4-300x150.jpg?fit=crop&auto=format) When doctors first discovered the tumor in his pancreas in 2003, Steve Jobs was told that, with immediate surgery, the tumor could be removed and he had a high possibility of being cured. Instead, the co-founder of Apple declined the surgery and focused on using alternative medicine to treat his disease. Harvard medical school researcher, Dr. Ramzi Amri, referred to Jobs’ death at age 56, “unnecessarily early” due to his reliance on alternative medicine. Amri argued that Jobs reduced his chances of survival by resisting his doctors’ recommendations of immediate surgery after the 2003 diagnosis. “Given the circumstances it seems sound to assume that Mr. Jobs’ choice for alternative medicine could have led to an unnecessarily early death.” He added that based on his own research and other sources from biomedical research, the neuroendocrine tumor that Jobs was diagnosed with could have been cured had it not been for his decision to try alternative medicine. [Steve Jobs' Trust in Alternative Medicine Likely Shortened His Life, Researcher Contends](http://articles.nydailynews.com/2011-10-14/news/30293918_1_alternative-medicine-pancreatic-cancer-neuroendocrine-tumor) \[New York Daily News\] After nine months of undergoing alternative medicine treatments for his disease, Jobs decided to allow for the use of conventional medicine in July 2004 due to the size of his tumor increasing. Jobs practiced Buddhism and was reportedly skeptical about mainstream medicine, instead stubbornly believing in unconventional methods to cure his ailments. Still, Dr. Jeffrey A. Norton, chief of surgical oncology at Stanford University, stated, “surgery is the only treatment modality that can result in a cure.” Norton was the one who removed Jobs’ tumor but alternative forms of treatment, such as a specialized diet and different meditation exercises, could have ultimately cost Jobs his life. Buddhist theories of medicine point to “three poisons” that cause people to get sick: greed, anger, and ignorance. Yet, why would a man who is so technologically-savvy as Steve Jobs be basing such important health decisions on ancient philosophies and natural remedies, especially when there have recently been more breakthroughs in cancer research than at any other point in history? [Did "Alternative Medicine" Kill Steve Jobs?](http://www.celebritydiagnosis.com/2011/10/did-alternative-medicine-kill-steve-jobs/) \[CelebrityDiagnosis.com\] In terms of his alternative medicine treatments, it is still not known what exactly Jobs did to treat his cancer. He did reportedly restrict his diet to only fruits or fruits and vegetables, consulted psychics, and tried a procedure known as hydrotherapy. Surgical removal of the tumor for patients whose disease is detected while it is still confined to the pancreas, have a five-year survival rate of 87 percent. Thus, the majority of patients live for quite a while. It is impossible to know whether surgery would have cured Jobs of his disease but his alternative medicine techniques, like acupuncture, were “not enough to change the course of the disease,” says Dr. Lowell Kobrin, a medical doctor who now focuses on acupuncture and herbal medicine at Northbend Medical Center in Coos Bay, Oregon. Kobrin added that the therapy could not affect cancer itself. Tim Birdsall, vice president of integrative medicine at the Cancer Treatment Centers of America, stated, “Once a cancer is established, in the vast majority of cases, simply changing the environment will not be sufficient to eradicate that established tumor.” While alternative medicine seems to be a beneficial compliment to conventional medicine, it cannot replace conventional medicine when trying to cure a dangerous disease. [Did Alternative Medicine Extend or Abbreviate Steve Jobs' Life?](http://www.scientificamerican.com/article.cfm?id=alternative-medicine-extend-abbreviate-steve-jobs-life&page=3) \[Scientific American\] Due to Jobs’ form of pancreatic cancer being less lethal that the most common form of pancreatic cancer known as adenocarcinoma, many experts believe that his decision to wait before opting for surgery was not necessarily a bad idea. Julie Fleshman, president and chief executive officer of the Pancreatic Cancer Action Network, said that patients in Jobs’ situation don’t automatically have to rush treatment. “The length of time before you have to make a decision about your treatment is not as quick as someone whose been diagnosed with an adenocarcinoma,” she added. Dr. Maged Rizk, a gastroenterologist at Cleveland Clinic, believed that Jobs waiting nine months for surgery was a bad decision. She said, “if it is an islet-cell tumor and the cells are \[typical of early cancer\], and as long as you don’t have symptoms, you can sit on it a bit.” Still, both Fleshman and Rizk agreed that alternative medicine treatments should not have been the sole methods of treatment for his disease. [Did Alternative Medicine Kill Steve Jobs?](http://www.livescience.com/16551-steve-jobs-alternative-medicine-pancreatic-cancer-treatment.html) \[LiveScience.com\] With the general consensus of medical experts being against the singular use of alternative medicine without conventional treatment, Steve Jobs agreed with them toward the end. Walter Isaacson, whose much-anticipated authorized biography on Jobs’ life is was released earlier this month, said that, before he died, the 56-year old Jobs had come to realize the mistake he made regarding his treatment. Isaacson said Jobs “wanted to talk about it, how he regretted it. I think he felt he should have been operated on \[it\] sooner.” Jobs was pushed to embrace conventional medicine by many confidants, including his sister, Mona Simpson, and Art Levinson, an Apple board member. In the end, Jobs realized the mistake he made and regretted the decision he made to fight the disease that plagued him for so many years. [Steve Jobs 'Regretted Trying to Beat Cancer with Alternative Medicine for So Long'](http://www.telegraph.co.uk/technology/apple/8841347/Steve-Jobs-regretted-trying-to-beat-cancer-with-alternative-medicine-for-so-long.html) \[The Telegraph\] ### Newsletter Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.
Shard	73 (laksa)
Root Hash	1719923596006174473
Unparsed URL	com,hcplive!www,/view/is-alternative-medicine-to-blame-for-the-death-of-steve-jobs s443